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, 40 million people worldwide suffer from epilepsy. Despite the availability of a 
large number of anticonvulsants, up to 30 % of patients are still refractory to 
treatment. Identification of the pharmacophore of triazoline has led to the 
development of the hydrophobic and lipid soluble novel aminoalkylpyridine (AAP) 
anticonvulsants, of which the N- [4-(chlorophenyl)]-1 -[4-^)yridyl)] ethylamine 0^-Cl 
AAP) has been shown to possess the highest anti-epileptic activity. However the 
mechanism of its action, and its pharmacokinetic and metabolic fate have not been 
fully understood. The aims of the present study are to study preformulation 
parameters of this novel of aminoalkylpyridine anticonvulsant and to investigate its 
metabolic and pharmacokinetic fate in laboratory animal. 
The physicochemical properties (preformulation parameters) of five structurally 
related aminoalkylpyridines, naimly p-¥, p-Cl, p-Br, />-CH3, m-CF3 AAPs, have been 
studied, including partition coefficient, aqueous solubility, and thermal behaviour. 
The p-¥, p-Cl, p-Br and j9-CH3 AAPs exhibited partition coefficients which were 
statistically indistinguishable within experimental errors. The relatively low partition 
coefficient of w-CF3 AAP (37.23 土 1.2) may be attributed to the increased ionization 
of the m-CF3 substituted aniline leading to a larger fraction of the compound being 
partitioned in the aqueous phase. The solubilities of AAPs depended on the 
substituent on the benzene ring and decreased in the order: p-F > j9-CH3 > p-Cl > p-Br 
> m-CF3. The enthalpy of solution (AH') of three halogen-substituted AAPs showed 
no statistically significant difference while the p-CH3 AAP had the lowest AH^  (20.24 
土 1.1 kJ/mol) and m-CF3 AAP had the highest AH' (34.76 士 1.8 kJ/mol). The enthalpy 
of fusion, AH^ of the AAPs are similar in magnitude to AH® (being lower by 1-6 
kJ/mol), suggesting that the aqueous solubilities of the AAPs are governed 
predominantly by solute-solute interaction in the solid state. Thermogravimetric 
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analysis and differential scanning calorimeteric studies on AAPs demonstrated that 
these compounds do not contain any solvent of crystallization and are relatively 
, thermostable. 
A sensitive and specific high performance liquid chromatographic (HPLC) assay 
for p-C\ AAP and its putative metabolites in rat urine has been developed and fully 
validated. HPLC analysis of户-Cl AAP in rat blood has also been developed. 
Preliminary pharmacokinetic studies were performed in conscious rats after 
intravenous administration ofp-C\ AAP. The elimination half-life was reasonable (5.0 
hour) and the clearance was extensive (1779.4 ml/hr). The volume ofdistribution was 
high (12.71 L/kg) indicating extensive extravascular distribution. The area under 
curve (AUC) was 11.84 ^ig/ml hr'\ 
Six novel metabolites were detected following intraperitoneal administration of 
p-Cl AAP to conscious rats. LC/MS analysis revealed that these metabolites have the 
following possible chemical structures: A^-[4-(2-hydroxychlorophenyl)]-l-[4-(2,6-
dihydroxypyridyl)]ethylamine, N- [4-(chlorophenyl)] -1 -hydroxy-1 - [4-
(pyridyl)]ethylamine, 2- [4-(chlorophenyl)] amino-2- [4-(2,6-
dihydroxypyridyl)]ethanoic acid, N- [4-(chlorophenyl)]-1 - [4-(pyridyl N-
oxide)] ethylamine, N-[4-(chlorophenyl)]-1 - [4-(2-hydroxypyridyl)] ethylamine and 2-
4-(chlorophenyl)]amino-2-[4-(pyridyl)]ethanaL Although the proposed biologically 
active metabolite, p_amino alcohol of>-Cl AAP, has not been identified in the present 
study, its further biotransformed metabolites, such as amino aldehyde and amino acid 
have been found. The results suggested that the proposed metabolic pathway may 
have an important learning on its anti-epileptic effect. 
Trace amounts of the p-C\ AAP were found in the 0-24h urine of control and 
phenobarbitone-pretreated rats (0.28 士 0.07o/o and 0.18 土 0.002o/o). This suggests that 
most of the p-C\ AAP was either metabolized or retained inside the body. It was 
found that pretreatment with phenobarbitone significantly increases urinary excretion 
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of all identified metabolites except for 2-[4-(chlorophenyl)]amino-2-[4-(2,6-
dihydroxypyridyl)]ethanoic acid and 2-[4-(chlorophenyl)]amino-2-[4-
(pyridyl)]ethanal. This suggests that phenobarbitone induced the enzyme system 
responsible for the metabolism ofp-C\ AAP in rats. 
XV 
摘 要 
、 全 世 界 超 過 四 億 人 患 有 癲 癇 症 。 雖 然 坊 間 有 很 多 
抗 癲 癇 藥 ， 但 三 成 以 上 患 者 的 病 程 仍 難 以 控 制 。 確 認 出 
三 哩 時 木 的 藥 效 團 ， 從 而 發 展 出 疏 水 和 脂 溶 的 新 抗 癲 癇 
藥——氨基院基口比口定。其中以 | [ 4 - (氯苯基 ) ] - 1 - [ 4 - (啡匕口定基 ) ] 
乙 胺 顯 示 出 最 高 的 抗 癲 癇 效 用 ° 但 是 它 的 作 用 機 制 、 
藥 物 動 力 學 和 代 謝 的 資 料 仍 未 充 份 明 白 。 這 類 新 的 抗 
癲 癇 藥 的 準 方 劑 設 計 特 點 、 在 實 驗 老 鼠 中 的 藥 物 動 力 學 
和 代 謝 情 況 將 爲 本 硏 究 的 範 圍 。 
五 種 結 構 相 關 的 氨 基 院 基 ^ t 淀 的 物 理 化 學 特 質 
( 準 方 劑 設 計 特 點 ） 硏 究 ， 包 括 它 們 的 分 配 系 數 、 水 溶 性 
和 對 熱 度 的 表 現 。 在 實 驗 誤 差 中 ， 對 氟 、 對 氯 、 對 溴 和 
對 甲 基 氨 基 院 基 • 比 淀 的 分 配 系 數 ， 在 統 計 層 面 上 沒 有 
差 異 。 而 間 三 氟 甲 基 氨 基 院 基 口 比 淀 的 系 數 卻 相 對 地 爲 
最 小 （ 3 7 . 2 3 ± 1 . 2 ) ， 可 能 因 爲 在 苯 胺 中 的 間 三 氟 甲 基 取 代 基 
的 電 離 作 用 較 其 他 的 取 代 基 爲 高 ， 因 而 引 致 較 多 的 化 
合 物 分 配 於 水 溶 態 中 。 氨 基 院 基 口 比 淀 的 水 溶 度 ， 亦 受 
著 苯 環 的 取 代 基 影 響 ， 其 次 序 爲 ： 對 氟 > 對 甲 基 > 對 
氯 > 對 溴 > 間 三 氟 甲 基 。 三 種 鹵 素 取 代 的 氨 基 院 基 味 匕 
口 定 的 溶 解 作 用 熱 函 轉 變 在 統 計 上 沒 有 分 別 ， 對 甲 基 氨 
基 院 基 • 比 淀 的 最 小 ， 每 一 摩 爾 爲 2 0 . 2 4 ± 1 . 1 千 焦 耳 ； 而 間 
三 氟 甲 基 則 爲 最 高 ， 每 一 摩 爾 爲 3 4 . 7 6 ± 1 . 8 千 焦 耳 。 它 們 熔 
融 和 溶 解 作 用 的 熱 函 ， 在 熱 量 上 亦 差 距 不 大 （ 只 有 每 一 
摩 爾 一 至 六 千 焦 耳 ） 。 由 此 推 論 出 它 們 的 水 溶 度 ， 主 要 
是 受 著 固 體 狀 態 中 溶 質 與 溶 質 的 相 互 作 用 影 響 。 氨 基 
院 基 ^ t 淀 的 熱 重 量 分 析 和 微 分 掃 描 量 熱 的 學 習 則 顯 示 
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出 它 們 比 較 耐 熱 ， 而 且 並 沒 有 與 溶 劑 產 生 結 晶 作 用 ° 
本 硏 究 發 展 了 一 個 敏 感 和 獨 特 ， 專 爲 分 析 和 確 認 
老 鼠 尿 液 中 的 對 氯 氨 基 院 基 口 比 淀 和 其 推 定 代 謝 物 之 高 
� 
效 液 項 分 析 法 ， 並 且 全 面 將 它 確 認 爲 有 效 ° 
爲 初 步 探 硏 對 氯 氨 基 院 基 口 比 淀 的 藥 物 動 力 學 ， 它 
將 以 靜 脈 注 射 方 式 注 射 到 淸 醒 的 老 鼠 上 ° 此 藥 的 半 衰 
期 頗 長 （ 五 小 時 ） ， 而 淸 除 率 則 很 大 （ 每 小 時 一 千 六 百 九 十 
九 點 — — 毫 升 ） 。 它 的 分 佈 體 積 很 大 （ 十 二 點 二 六 公 升 ） ， 
反 影 出 有 很 廣 泛 的 體 內 外 分 佈 ， 而 藥 時 曲 線 下 面 積 則 
爲 每 小 時 每 毫 升 十 一 點 七 七 微 克 。 
腹 腔 注 射 對 氯 氨 基 院 基 口 比 淀 到 淸 醒 的 老 鼠 ， 因 而 
探 測 到 六 種 新 的 代 謝 物 。 透 過 液 體 色 層 分 析 / 質 譜 分 
析，它們的化學結構推論爲：从 [ 4 - ( 2-羥氯苯基 ) ] - 1 - [ 4 - ( 2 , 6-雙 
羥口比卩定基)]乙胺、Aq4-(氯苯基 ) ] -1-羥-1- [4-(口比卩定基)]乙胺�2-
[4(氯苯基)]氨基-2-[4-(2,6-雙經口比口定基)]乙酸、iV-[4-(2-氯苯基)]-1-
[4-(口比口定基-7^-氧化物)]乙胺、A44-(氯苯基)]-1-[4-(2-羥口比旋基)] 
乙胺和 2 - [ 4 - (氯苯基 ) ]氨基 - 2 - [ 4 - (口比淀基 ) ]乙醛。雖然並沒有 
直 接 發 現 構 思 中 的 卩 - 氨 基 醇 ， 但 它 的 繼 後 轉 變 代 謝 物 ’ 
例 如 氨 基 醛 和 氨 基 酸 卻 被 發 現 ， 這 結 果 顯 示 出 的 代 謝 
路 線 卻 和 這 藥 的 抗 癲 癇 作 用 有 關 。 
不 論 曾 接 受 與 非 接 受 苯 巴 比 妥 注 射 的 老 鼠 ， 在 二 
十 四 小 時 內 的 尿 液 中 ， 只 探 測 到 小 量 的 對 氯 氨 基 院 基 
口比口定（佔注射分量的0.28土0.07和0.18±0.002 %) ° 可 能 因 爲 大 
部 份 的 對 氯 氨 基 院 基 已 經 代 謝 了 ， 又 或 遺 留 在 身 體 裏 。 
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在 接 受 了 苯 巴 比 妥 的 老 鼠 尿 液 中 ， 除 了 2-[4(氯苯 
基 ) ]氨基 - 2 - [ 4 - ( 2， 6 -雙羥口比淀基 ) ]乙酸和 2 - [ 4 - (氯苯基 ) ]氨基 - 2 - [ 4 -
, ( • 比 淀 基 ) ] 乙 醛 ， 其 他 的 代 謝 物 均 有 顯 著 增 加 ° 可 能 因 爲 
苯 巴 比 妥 可 能 誘 發 負 責 對 氯 氨 基 院 基 口 比 淀 的 代 謝 之 
« 系 統 功 能 。 
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1 INTRODUCTION 
1.1 Definition and Prevalence of Epilepsy 
The word "epilepsy" is derived from a Greek word meaning “to take hold of’. 
Epilepsy is not a disease but a chronic disorder of intermittent and recurrent 
disorganized electrical activity in the brain, which causes a fit or seizure. Seizures are 
characterized most commonly by impairment of motor activity (a convulsion) or 
consciousness. The type of seizure depends upon the part of the brain where the 
abnormal electrical discharge arises. Many varieties of epileptic seizures occur, and 
frequency and form of attacks vary greatly from person to person. Since the 
definitions ofepilepsy and the types of seizures are numerous, a specific classification 
system is being promoted by the International League Against Epilepsy. The 
International Classification of Epilepsy Seizures has been adopted by the medical 
community and is gradually replacing outdated seizures terminology including "grand 
mal" and "petit mal". The new classification scheme describes seizures as being of 
two major types, viz: “partial，，and "generalized", defined respectively as excessive 
electrical discharge being limited to one area of the brain and that involving the whole 
brain. It further divides each of these categories into simple partial, complex-partial, 
absence, tonic-clonic, and other types. 
With regard to the prevalence of epilepsy, there are no geographical, racial or 
social class boundaries. Anyone can be affected by seizures. Epilepsy can occur in 
both sexes of any age, especially infancy, childhood, adolescence and old age. 
According to the data from the World Health Organization (Fact sheets N165, June 
1997), up to 5% ofthe world's population may have a single seizure at some time in 
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their lives. The prevalence of a disorder is the proportion of a population with that 
disorder at a given point in time. The mean prevalence of active epilepsy (i.e. 
continuing seizures or the need for treatment) from many studies around the world is 
approximately 7 per 1000 of the general population. Thus, 40 million people in the 
world have epilepsy at any one time. This may be an underestimate as some studies in 
developing countries (Colombia, Ecuador, Liberia, Nigeria, Panama, Tanzania and 
Venezuela) suggest a prevalence ofmore than 10 per 1000. The lifetime prevalence of 
epilepsy, i.e. the number of people presently in the world who have epilepsy now or 
have had it in the past (e.g. childhood) or will get it in the future (e.g. old age), rises to 
approximately 100 million people. 85% of the people affected by epilepsy live in 
developing countries where the great majority has little or no access to treatment. 
Recent studies in both developed and developing countries have shown that up to 
70% ofnewly diagnosed children and adults with epilepsy can be successfully treated 
(complete control of seizures for several years) with anti-epileptic drugs. After two to 
five years of successful treatment, drugs can be withdrawn in about 70% of children 
and 60% of adults without relapses. However, up to 30% of patients may not respond 
to drug therapy. 
1.2 Neurophysiology and Pathophysiology of Epilepsy 
The normal neuronal resting membrane potential results from the maintenance 
of an intracellular electrolyte concentration that is high in K+ and low in Na+ relative 
to the extracellular fluid concentration. With excitatory postsynaptic depolarization 
sufficient to generate an action potential, Na+ moves intracellularly and K+ flows out. 
During repolarization, Na+ extrusion is coupled with K+ uptake and the utilization of 
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ATP to reestablish the membrane potential. Inhibitory postsynaptic potentials 
hyperpolarize the neuron and an action potential is not generated. Depolarization of 
� the presynaptic ending is associated with release of neurochemical transmitters that 
are specific for the neuron involved. Acetylcholine, y-amino butyric acid (GABA), 
norepinephrine, dopamine, 5-hydroxytryptamine, glycine, and glutamic acid may be 
neurotransmitters in the brain or spinal cord. Any events that alter the synthesis, 
release, sensitivity to, or inactivation of neurotransmitters affect the excitation or 
inhibition mediated by the compound. Such inhibitors normally act by promoting 
chloride uptake into the neuron using the chloride ionophore membrane pump; this 
increases membrane potential and so stabilizes it. 
Epileptic seizures indicate a functional impairment of neuronal activity. 
Within nervous tissue, information is sent via action potentials, which are transmitted 
across synapses from neuron to neuron. There is normally directionality of the 
impulses and specific patterns of transmission determined by anatomic and functional 
connections. The electrochemical activity of the brain produces potential differences 
that can be measured by electroencephalography (EEG). In a patient with epilepsy, 
the EEG is abnormal, the characteristic wave forms being altered by the appearance of 
spikes ofelectrical activity. The type ofEEG activity seen in epilepsy is known as the 
spike wave. The spike activity is considered to be the summated, synchronized 
electrical activity of a group of disordered neurons at an epileptogenic focus, which is 
known as a paroxysmal depolarization shift (PDS). When cells at the seizure focus 
fire, they normally excite inhibitory intemeurons, which release GABA. This 
inhibitory neurotransmitter causes the focus to tum off and also inhibits the 
surrounding cells. When seizure activity does occur, some mechanisms seem to 
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override the surrounding inhibition and decrease the degree of hyperpolarization that 
usually occurs after the PDS. 
, Excitatory amino acids may also play an important role in epilepsy. Hayashi 
reported that sodium glutamate and aspartate, when applied topically onto the cerebral 
cortex of dogs and primates, induced clonic convulsions (Hayashi, 1952). 
Endogenous excitatory amino acids include glutamate, aspartate, L-homocysteate, L-
homocysteine sulphinate and quinolinic acid. All these compounds elicit epileptic 
seizures after either systemic injection or focal injection directly into the brain 
(Johnston, 1973; Stone and Javid, 1983). Thus there exists two opposite but 
complementary strategies for tackling the epilepsy. The first and widely used method 
is to enhance the function of inhibitory compounds (Meldmm, 1984). The alternate 
method is by impairing the excitatory amino acids using excitatory amino acid 
antagonists. 
1.3 Drugs Currently Used in the Treatment of Epilepsy 
Phenobarbital was first reported to be a clinically effective anticonvulsant in 
the early 19^ ^ century (Hauptman, 1912). To this day it remains one of the major 
anticonvulsant drugs. It has the widest spectrum of activity in different seizure 
patterns, and many anticonvulsant drugs are structural derivatives of this barbiturate, 
for example, mephobarbital, eterobarb and deoxybarbiturate (primidone). 
Primidone, a 2-deoxybarbiturate, is a polar compound that is well absorbed 
and distributed. It was reported to be clinically effective as an anticonvulsant 
(Handley and Stewart, 1952) and possessed anticonvulsant activity against various 
experimental models of epilepsy (Baumel et al., 1973). It appeared to exert its action 
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by reducing sustained high-frequency repetitive firing of action potentials through 
delaying the recovery of sodium channels from activation. 
Phenytoin, which can also be considered as a structural analogue of 
phenobarbital, has also been shown to be effective against seizures (Merritt and 
Putnam, 1938). It can produce a selective blockade of high-frequency repetitive 
neuronal firing by binding to sodium channels. It also blocks the voltage-dependent 
calcium channels. Phenytoin has been reported to depress excitatory transmission by 
both pre- and post-synaptic mechanisms. Since it does not have the sedative 
properties of barbiturates, it was considered to be less toxic than phenobarbital. 
However, this is certainly not the case, and the wide range of toxic effects of 
phenytoin has been reemphasized (Glaser, 1972). The toxic effects may be related to 
its dose-dependent kinetics (Gerber et al., 1971), individual variations in metabolism 
(Andreasen et al., 1973), drug interactions (Hansen et al., 1966; Brennan et al., 1970; 
Christiansen and Dam, 197,3) and chronic side-effects (Buchthal and Svensmark, 
1960). 
Valproate was subsequently demonstrated to have a broad spectrum of 
anticonvulsant activity in a wide variety of animal seizure models (Chapman et at., 
1982; Loscher, 1988). Its mode of action is similar to those of phenytoin and 
primidone mentioned above. However, valproate is only weakly protective against 
seizures induced by excitatory amino acids (Chapman et al., 1982; Ferrendelli et aL, 
1989). In addition, the drug causes motor toxicity in animals at doses that are close to 
those required to protect against seizures. For the maximal electroshock test, the 
protective index is only 1.6 compared to a value of 6.9 for phenytoin (Swinyard et aL, 
1989). 
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Several acetylurea compounds have been used as anticonvulsants, as have 
other structurally related derivatives. The prototype drug, phenylacetylurea, has 
, significant efficacy for preventing generalized tonic and/or clonic seizures, absence 
seizures, and many partial seizures. Unfortunately, it is also one of the most toxic 
anticonvulsant drugs. 
Carbamazepine is another major anticonvulsant with significant efficacy for 
preventing partial seizures and for generalized tonic and/or clonic seizures (Julien and 
Hollister, 1975). Carbamazepine is an iminostilbene derivative and as such represents 
a new chemical class of anticonvulsants. However, the conformation ofthe compound 
is quite similar to that ofthe barbiturates and hydantoins. It has a similar spectrum of 
anticonvulsant activity to phenytoin in animal seizure models. Its mode of action is 
similar to phenytoin in that it inhibits voltage-dependent sodium channels. Interaction 
with adenosine receptors (Lewin and Bleck, 1977) may also be involved but not for 
the phenytoin. Toxicity with carbamazepine is relatively minor. The most serious 
effect is its ability to suppress bone marrow function and possibly to produce an 
aplastic anemia which may be fatal. Sulfonamides (developed in 1959), 
benzodiazepines (developed in 1970) and dipropylacetic acid (developed in 1973) are 
also commonly used anticonvulsants. 
Recently, a number of new anticonvulsants have become available. Five 
promising ones include vigabatrin (Lippert et al., 1977), gabapentin (Bartoszyk et al., 
1986), felbamate (Swinyard et al., 1986), lamotrigine (Miller et al., 1986) and 
oxcarbazepine (Jensen et al., 1991). Lamotrigine and vigabatrin, being more 
frequently prescribed, are discussed below. 
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Lamotrigine is effective as an adjunct agent in the treatment of complex and 
simple partial seizures with or without secondary generalization. It has a favourable 
� pharmacokinetic profile, including a long half-life, low serum protein binding, and 
lack ofmixed-function oxidase enzyme induction (Gilman, 1995). Adverse effects are 
primarily related to the central nervous system, the most common ones being 
dizziness, diplopia, ataxia, and somnolence. However, the occurrence ofrash can limit 
its use. 
The GABA analog vigabatrin is a specific, enzyme-activated inhibitor of the 
GABA catabolic enzyme, GABA-T. Vigabatrin becomes covalently linked to GABA-
T at its active site and thereby causes an irreversible inhibition of the enzyme (Lippert 
et aL, 1977). Since transamination by GABA-T represents the only important pathway 
for catabolism of brain GABA, the irreversible inhibition of GABA-T by vigabatrin 
results in a prolonged elevation in brain GABA levels (Jung et al., 1977). The 
anticonvulsant effect of vigabatrin is related to its inhibitory effect of the GABA-T. 
However, in mice, rats, dogs, and perhaps monkeys, vigabatrin produces a dose-
related microvacuolization ofthe outer lamellar sheaths of myelinated axons, an effect 
referred to as “intramyelinic edema" (Butler et al., 1987; Butler, 1989; Graham, 
1989). 
In general, there are three ways for tackling epilepsy through drug therapy. 
The present anticonvulsants may target non-synaptic, pre-synaptic or post-synaptic 
action on neurotransmission. 
The non-synaptic action involves reduction of sustained repetitive firing of 
action potentials due to opening of voltage-dependent sodium channels (McLean and 
MacDonald, 1981; McLean and MacDonald, 1982; MacDonald and McLean, 1982). 
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It is thought that some drugs, for example, phenytoin, carbamazepine and felbamate, 
slow the recovery of these channels thus producing a frequency-dependent block on 
， sodium ion transport and a subsequent decrease in transport of the impulse along the 
axon. 
As an example for the pre-synaptic action of anticonvulsants, lamotrigine acts 
at voltage-dependent sodium channels resulting in decreased presynaptic release of 
glutamate (Leach et al., 1986). An inhibitory pre-synaptic role has been postulated for 
valproate. Certainly valproate produces an increase in total brain GABA 
concentration (Godin et al., 1969) which is only partly explained by a decrease in 
post-synaptic metabolism and it is proposed that it may exert its effect by activation of 
GABA synthesis pre-synaptically (Loscher, 1981). 
The post-synaptic inhibition of neurotransmission can act either through the 
enhancement of the inhibitory mechanisms of GABA or other amino acid inhibitors, 
or through the direct reduction of excitatory mechanisms. Vigabatrin was developed 
as an enzyme-activated, irreversible inhibitor of GABA transaminase, the primary 
degradative enzyme of GABA; by decreasing the catabolism of GABA, it increases 
the inhibitory action of GABA. Phenobarbitone is the only anticonvulsant that has 
been shown to enhance GABA action and shows a reduction in excitatory mechanism, 
namely, an antagonism of glutamate responses. 
1.4 Triazolines and Aminoalkylpyridines as a New Class of Potential 
Antiepileptic Drugs 
Recently, the 1,2,3-triazolines have assumed considerable importance as a new 
class of potential anticonvulsant drugs (Kadaba, 1984a). This new class of 
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anticonvulsants was first discovered by Wolff in 1912 during the studies on the action 
of organic azides on quinones (Wolff, 1912). 
Triazolines are normally prepared by the 1,3-cycloaddition of diazomethane to 
•% 
Schiff Bases in dioxane solution, in the presence of water (Kadaba, 1988; Kadaba et 
al., 1984b). The unique ring system of triazolines is a five-membered ring which 
contains three nitrogen, two carbon atoms and a double bond (Figure 1.1). 
The unique ring system of triazolines is different from those of the 
conventional anticonvulsant drugs in that most of them possess a dicarboximide 
(ureylene) -CO-NH-CO- and/or ureide (-NH-CO-NH-) (Kadaba et aL, 1996) 
functional group as in barbiturates, hydantoins, succinimides, and oxazolidinediones 
or the structurally related primidones. The absence of the dicarboximide group, which 
contributes to the inherent hypnotic and sedative activity of the barbiturates and 
related compounds, is expected to reduce the toxic effects oftriazolines. 
Triazolines were evaluated for anticonvulsant activity (Kadaba, 1984a) using 
the maximal electroshock seizure (MES) test and the subcutaneous pentylenetetrazol 
(Metrazol) seizure threshold (scMet) test (Porter et al., 1984). In addition, CNS 
toxicity was determined (Kadaba, 1984a) using rotorod ataxia test (Dunham and 
Miya, 1957). The dose that elicits an anticonvulsant response in 50% of the animals 
( E D 5 0 ) , the median minimal neurotoxic dose ( T D 5 0 ) , the dose that causes death in 
50% ofthe animals in 2 4 hours ( L D 5 0 ) and the dose at which 50% of the animals lost 
their righting reflex (i.e., the median hypnotic dose, H D 5 0 ) were determined. The 
representative triazoline, [l-(4-chlorophenyl)-5-(4-pyridyl)-A^-l,2,3-triazoline], coded 
ADD17014 (Figure 1.1), has successfully advanced through all phases of preclinical 
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testing, including 14- and 30-day dose-range finding studies, in the NHs[DS-sponsored 
Antiepileptic Drug Development (ADD) Program (Porter et al., 1984). 
�-
^Qn-^-^^ 
^~"‘ H,C^ ^N X 2 Y 
Figure 1.1 Structure of triazoline. The j^ -Cl substituted triazoline is registered as 
ADD17014. 
The ratio of effective dose to toxic dose is an important consideration in the 
search for new drugs, and the E D 5 0 / T D 5 0 values, defined as the protective index (PI), 
for ADD17014 by the MES and s.c.Met. tests are 0.23 and 0.40 respectively. The oral 
ED50/i.p E D 5 0 ratio is taken as a measure ofthe oral activity and a value of less than 4 
is regarded as adequate. The oral ED50/i.p E D 5 0 values for ADD17014 as determined 
by the rotorod, MES and s.c.Met. tests are 0.62, 1.13 and 3.50 respectively, indicating 
adequate absorption of the drug in mice after oral administration. 
Investigations on the metabolism (Figure 1.2) and pharmacology of 
ADD17014, suggest that this novel anticonvulsant functions as a "prodrug" and exerts 
its anticonvulsant activity by impairing excitatory amino acid (EAA) L-glutamate 
neurotransmission via a unique "dual-action" mechanism (Kadaba et aL, 1996). While 
an active P_amino alcohol metabolite from the parent prodrug acts as an iY-methyl-D-
aspartate (NMDA)/MK-801 receptor blocker or the glutamate antagonist, the parent 
ADD17014 impairs the presynaptic release of L-glutamate. In vivo and in vitro 
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pharmacological studies ofADD17014 and its metabolites indicated that the p-amino 
alcohol (Figure 1.2) was the active species which inhibited the specific binding of 
, [^]MK-801 to the MK-801 site (by 56% at 10 ^iM), suggesting ADD17014 acts as a 
prodrug. In addition, ADD17014 significantly decreased Ca^^-dependent, K+-evoked 
L-Glutamate release (by 83% at 100 i^M) and the C1' channel activity (by 50-63%), a 
useful membrane action that reduces the excessive L-Glutamate release during 
epileptic seizures. ADD17014 and its metabolite, P-amino alcohol, together 
effectively impair both pre- and post-synaptic EAA neurotransmission. 
N & V " ^ ^ C I ^ O ^ t Z ^ > C I 
H2 2 ^N^ 
Aziridine ^^^\^^ / ADD17014 
H+，H2O ^ v ^ Z H+，H2O 
N ^ ^ ? - N H " ^ ^ C I 
~ CH2OH ^ ~ ^ 
p-amino alcohol 
Figure 1.2 Metabolism ofADD17014. 
A careful inspection of the structure of triazoline ADD17014 and its potential 
metabolites reveals the presence of a common "structure-element" comprising an 
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‘open, "two-carbon-one-nitrogen" framework with the pyridyl and phenyl substituent 
groups incorporated onto the respective carbon and nitrogen atoms (Deshmukh and 
� Kadaba, 1993). This 'open' structure probably constitutes the primary nucleus ofthe 
"hidden" pharmacophore of ADD17014, and is present in the aziridine an the P_ 
amino alcohol metabolites. However, being non-lipophilic, the p-amino alcohol 
cannot cross the blood brain barrier (BBB) and hence fails to demonstrate the seizure 
protection in both MES and s.c.Met tests in mice (Kadaba, 1990). On the other hand, 
aziridine, though a prodrug per se and having lipophilicity very similar to that of the 
parent ADD17014, shows no activity at any of the receptor sites mentioned in above 
section. 
Apparently, the “open flexible" structure of the pharmacophore nucleus is a 
prerequisite for activity at postsynaptic receptor sites; the closed ring structures in the 
triazoline and aziridine impart a certain degree of rigidity to the pharmacophore 
nucleus and prevent it from attaining the proper configuration for receptor interaction. 
Indeed, the open-chain form of the aziridine gives rise to the aminoalkylpyridine 
(AAP) structure; it contains the open flexible pharmacophore element of the P-amino 
alcohol and bears a remarkable structural relationship to the P-amino alcohol as the 
respective "deoxy-analogue". 
Elucidation ofthe hidden pharmacophore nucleus of the ADD17014 prodrug 
leads to the logical and directed evolution of the hydrophobic, lipid soluble AAPs, in 
which the hydroxymethyl group of the p-amino alcohol is replaced by a non-polar 
methyl-moiety. The AAPs constitute a unique class ofthe 1,2,3-triazoline metabolite 
analogues; unlike the hydrophilic amino alcohol metabolite, these hydrophobic 
metabolite analogues are potent, orally active anticonvulsants. 
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1.5 Chemical Synthesis of Aminoalkylpyridines 
The structures ofthe ADD17014 pharmacophore andp-C\ AAP are shown in 
� Figure 1.3. AAP is synthesized in a two-step reaction (Figure 1.4). 4-acetylpyridine is 
condensed with a substituted aniline to yield the respective ketimine. Molecular sieves 
are used to trap the water molecules formed during the reaction; their presence is 
essential for the successful completion of the reaction leading to a reasonably good 
product yield. The ketimine thus formed is then reduced by sodium borohydride in 
refluxing ethanol. 




Figure 1.3 Pharmacophore ofADD17014 (a) and structure of p-Cl AAP (b). 
The reaction mixture is cooled, treated with dilute hydrochloric acid to decompose 
excess sodium borohydride and then basified with 10% sodium hydroxide solution, to 
obtain the AAP. The compound is recrystallized from acetone-petroleum ether or t-
butyl methyl ether-petroleum ether mixture to give yields ranging from 50-80%. 
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V > r �+ N H 2 " Q > V ^ ? = N ^ ^ 
CH3 ^ ~ ‘ X • CH„ “ ^ sieves, reflux, stir, 4n 3 
4-Acetylpyridine Anilines Ketimine 
^ = = ^ NaBH4,95% EtOH ^ = ^ H / ^ 
v > c : H A > v > 0 � x 
^"3 reflux, stir, 4h. 3 
Ketimine AAP 
Figure 1.4 Synthesis of aminoalkylpyridines. 
1.6 Metabolism of Aminoalkylpyridines 
Figure 1.5 shows the potential metabolic pathway of AAPs. AAP is thought to 
be metabolized to p-amino alcohol that functions as a glutamate antagonist and may 
further oxidize to a-amino acid. AAP may transform into hydroxylamine, which may 
further metabolize to nitrone. AAP may also oxidize to A^-oxide or carbinolamine. The 
latter may cleave to 4-acetylpyridine and aniline. The resulting metabolites may 
undergo further phase II transformation. 
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Figure 1.5 Potential metabolic pathway of aminoalkylpyridines. 
1.7 Anticonvulsant Activities of Aminoalkylpyridines 
It has been demonstrated that the AAPs afford seizure protection in both mice 
and rats, although their activity by the oral route far exceeds that observed by the i.p. 
route. They are highly effective in a dose-dependent fashion in the MES test 
(Deshmukh and Kadaba, 1993). In contrast to i.p. administered compounds, the 
protective effects of orally administered AAPs reach a peak more slowly and are 
sustained for up to 4h or longer. Similarly, the doses causing motor impairment are 
also substantially higher in rat, p.o. than in mouse, i.p. and no apparent signs of 
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neurological deficit are observed up to 500 mg/kg in the rat, which is well reflected in 
the P.L values. For thep-C\ AAP, the ED50(MES) and T D 5 0 in mouse i.p. are 53.7 and 
� 160.1 mg/kg respectively and the P.L value is 3.0. In the case of p.o. administration to 
the rat, the ED50(MES) is 22.9 mg/kg and P.L value is greater than 20.5. 
As the triazoline pharmacophore is an integral part ofthe AAPs, the latter may 
act by a similar mechanism to glutamate antagonists. Indeed preliminary receptor 
displacement and release studies using p-C\ AAP indicate that the ability of the 
triazoline structure to impair presynaptic glutamate release is fully retained or better 
in this compound (74% at 50 i^M and 80% at 100 ^iM), as with the postsynaptic 
activity of the p_amino alcohol, albeit at a different site; the p-C\ AAP compound 
weakly displaces [^B] DTG, a ligand highly specific for the a-receptor (50% at 10 
i^M concentration) and shows no affinity for the NMDAy'PCP sites (Deshmukh and 
Kadaba, 1992). It indicates that anticonvulsant action of p-C\ AAP is not a result of 
interaction with these receptor sites. 
The AAP anticonvulsant agents exhibit low to moderate affinities, in the i^M 
range, and high selectivity for the ai site, and no affinity for a2 sites. The lack oflink 
to the NMDA receptors may account for the remarkable absence of motor toxicity in 
these compounds. The anticonvulsant activity of p-Cl AAP is possibly by inhibition 
of glutamate release rather than by the blockade of the NMDA receptor sites. 
The AAPs, a new generation of potent, orally active anticonvulsant agents, are 
far superior to the parent triazolines. The AAPs are highly lipophilic molecules that 
can cross the blood brain barrier (BBB), and show a high degree of anticonvulsant 
activity by the oral route with no apparent neurotoxicity and with P.L values greater 
than 20. 
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1.8 Aim and Scope of the Present Study 
The evolution of aminoalkylpyridines (AAPs) from 1,2,3-triazolines as a new 
� class ofpotential anticonvulsants has been published (Deshmukh and Kadaba, 1993). 
While the toxicology and pharmacological action of these compounds has been 
extensively studied (Deshmukh and Kadaba, 1992), there is no information available 
on the metabolic fate of these novel anticonvulsants in mammalian systems. Hence 
the main aim ofthe study is to investigate the in vivo metabolism of>-Cl AAP in rat, 
a representative AAP with proven anticonvulsant activity with a view to elucidating 
the mode of action of this novel anticonvulsant. 
Specifically, the project involved: 
1) physicochemical (preformulation) characterization of five structurally related 
AAPs (i.e. p-F, p-C\, p-Bx, p-CR^ and m_CF3 AAPs) including determination of 
partition coefficient, aqueous solubility, and thermal properties; 
2) development and validation of sensitive high performance liquid chromatographic 
methods for detection of>-Cl AAP and its metabolites in biological fluids; 
3) determination of the pharmacokinetic parameters in the rat following intravenous 
administration of j^-Cl AAP; and 
4) identification of the urinary metabolic profile following administration of p-C\ 
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2.1 MATERIALS 
� All aminoalkylpyridines (AAPs) and p-C\ aziridine (AZI-C1) were synthesized 
as previously described (Deshmukh, 1993). Heparin (sodium salt) was purchased 
from B. Braun Melsungen AG (D-34212, Melsungen, Germany) and dissolved in 
laboratory prepared physiological saline (0.9%, w/v) to a final concentration of 100 
I.U./ml. Sodium carbonate (Na2CO3), sodium bicarbonate ( N a H C O 3 ) , citric acid 
(C6H8O7.lH2O) and disodium phosphate (Na2HPO4) (Anala-R grade) were obtained 
from BDH Laboratory Supplies (England). All water used was freshly distilled, 
deionized and filtered. 
Delory and King's carbonate-bicarbonate buffer, pH 10.0 was prepared by 
mixing 53.4 ml of0.1 M sodium carbonate (10.6 g/L) with 46.6 ml of 0.1 M sodium 
bicarbonate (8.4 g/L). 
McIlvaine's citric acid-phosphate buffer was made up by mixing 9.8 ml of0.1 
M citric acid (21.0 g/L) with 91.2 ml of0.2 M disodium phosphate (28.4 g/L). All pH 
measurements were taken at 2 0 � C using a Hanna pH meter model HI 8418 (HANNA 
Instrument, USA) and all buffers were stored at 4 °C. 
Male Sprague-Dawley rats (body weight 250-300 g) were bred at and supplied 
by the Laboratory Animal Service Centre at The Chinese University of Hong Kong 
and were housed in a light-, temperature- and humidity-controlled environment. 
Animals were fed on standard rat food - RM3(E) from Special Diet Services Ltd. 
(Witham, Essex, U.K.) and allowed access to water ad libitum. 
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Octan-l-ol (GPR grade) was obtained from BDH Laboratory Supplies 
(England). For the partition coefficient determination, both n-octanol and the citric 
acid-phosphate buffer (pH 7.4) were pre-saturated with each other before use. 
Methanol, acetonitrile and diethylamine were HPLC grade purchased from 
BDH Laboratory Supplies (England). 
P-Glucuronidase (E. Coli K12) and P-glucuronidase/Arylsulfatase (Helix 
pomatia) were obtained from Boehringer Mannheim (GmBH, Germany). Acetate 
buffer (pH5.0) was prepared by diluting glacial acetic acid (pro analysis grade) from 
Merck, (Germany) with water (1.146 ml in 100 ml) and mixing with 35.2 ml of a 
solution of sodium acetate (pro analysis grade) (1.46 g in 100 ml water) from BDH 
Laboratory Supplies (England). The pH was adjusted and the volume made up to 100 
ml. The buffer was stored at 4 °C. p-Cl AAP was freshly prepared by dissolving in 50 
% p-cyclodextrin solution. Sodium salt of phenobarbitone was dissolved in laboratory 
prepared physiological saline. 
Ether for anaesthesia was obtained from BDH Laboratory Supplies (Poole, 
BH15, lTD, England). 
Translucent PE tubings (0.5 mm ID, 1.00 mm OD and 0.86 ID, 1.27 mm OD) 
were obtained from Portex (England). Needles (23G) and 1 ml syringes were 
purchased from B. Braun Melsungen AG (D-34212, Melsungen, Germany). 
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2.2 PREFORMULATION STUDIES ON AMINOALKYLPYRIDINES 
2.2.1 Determination of Partition Coefficients 
> 
Stock solutions of p-V, p-C\, p-Bx, j9-CH3 and m - C F 3 AAP (16 ^g/ml) were 
prepared in citric acid-phosphate buffer (pH 7.4). 25 ml of the stock solution was 
mixed with 2.5 ml n-octanol in a separating funnel and shaken for 10 minutes. After 
allowing the mixture to stand for 2 hours, the aqueous phase was collected and 
assayed for AAP by UV spectrophotometry (Shimadzu Model UV-160A 
spectrophotometer) at appropriate A-max (235.0, 250.4, 251.6, 241.4 and 247.6 nm for 
p F , j9-Cl, j9-Br, j 9 -CH3 and m - C F 3 AAP respectively). Six replicate determinations 
were performed for each AAP. Calibration curves covering the concentration range 0 
-15 ^ig/ml for the various AAPs were constructed. Each concentration was measured 
four times (n=4). 
2.2.2 Determination of Aqueous Solubilities 
The solubilities ofp-F, p-C\ j^-Br, p-CR^ and m-CF3 AAP from 2 5 � C to 60 
°C were determined as follows. Excess amounts of AAPs were placed in the citric 
acid-phosphate buffer (pH 7.4) in capped micro-centrifuge tubes and equilibrated for 
one week at a defined temperature in a thermostatic bath to ensure the attainment of 
equilibrium. The supernatant was pipetted and assayed for AAP by UV 
spectrophotometry (Shimadzu Model UV-160A spectrophotometer) at appropriate 
A^max (235.2, 250.0, 251.6, 242.6 and 247.4 nm for j^-F, p-C\, p-Bx, j9-CH3 and m-CF3 
AAP respectively). One week of equilibration time was considered adequate since the 
solubility did not show any further increase after three more days of equilibration. 
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Triplicate determinations were made for each AAP. Calibration curves for p-V, p-C\, 
j9-Br,j9-CH3 and m - C F 3 AAP covering appropriate concentration ranges in citric acid-
� phosphate buffer were constructed as described in the previous section. 
The solubility data was analyzed by Van't Hoff equation: 
A H solution 
ln Cs = + K 
RT 
2.2.3 Determination of Thermal Properties 
The melting point, Tm, and enthalpy of fusion, AH \ of various AAP samples 
of p-¥, p-C\, p-Br, p-CR3 and m - C F 3 AAP (1 - 2 mg) were determined in non-
hermetically sealed aluminium pans heated at a rate of 5 °C / min. in a DSC (Perkin 
Elmer DSC6) (U.S.A.) using nitrogen as the purge gas and indium as the calorimetric 
standard. The Tm was taken as the temperature at the point of intersection of the 
leading line of the steepest slope and the baseline. AH^ was calculated from the peak 
area which was determined by means of a DSC6 Software on an IBM computer 




r (Since AG = 0 during melting). 
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2.3 DEVELOPMENT OF A HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHIC ASSAY for p-CX AMINOALKYLPYRIDINE 
� 
2.3.1 HPLC Apparatus and Conditions 
The HPLC system consisted o fa gradient programmer (model 2360), a HPLC 
pump (model 2350), a variable wavelength UV/Vis detector (model V<®), and 
computing integrator hardware and software (ChemResearch 150) (all from ISCO 
Inc., Lincoln, U.S.A.). The column was a reversed phase Apex ODS 5ja (25 x 0.46 
cm) column (Jones Chromatography, Hengoed, U.K.). An ODS guard column 
(Alltech Associates, Inc., USA) was used to protect the analytical column. Samples 
were introduced into the system via a Valco injector fitted with a 20 i^l loop. 
Detection of the eluents was by UY absorption at 254 nm. Chromatograms and 
retention times were recorded, and peak areas were calculated by (computerised) 
electronic integration. The HPLC analysis was performed at ambient temperature. The 
mobile phase consisting of methanol : acetonitrile : water (30 : 30 : 40. v/v) and 
diethylamine (200 ^il/L) was eluted at 1 ml/min., and was filtered and degassed prior 
to use. 
2.3.2 Animal Treatments and Biological Fluid Collection 
Blank rat blood was obtained by cardiac puncture, and heparinised saline (100 
I.U.，60 i^l per ml of blood) was added to the blank blood. Blank rat urine was 
obtained from male Sprague-Dawley rats housed in perspex metabolic cages. The 
control blood and urine were stored at 4 °C. 
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2.3.3 Solid Phase Extraction 
C18 cartridges (Waters Corp., U.S.A.) used for solid phase extraction were 
pre-conditioned with 2 ml ofmethanol followed by 2 ml ofdistilled water before use. 
Following the loading of samples, the cartridge was washed with 2 ml of distilled 
water and then eluted with 2 ml ofmethanol. The eluents were evaporated to dryness, 
and the residues reconstituted with 100 i^l of the HPLC mobile phase prior to the 
chromatographic analysis. 
2.3.4 Construction of Calibration Curves for p-Cl AAP in Rat Blood 
The level of>-Cl AAP in blood varied markedly. In order to measure the p-C\ 
AAP levels accurately at both the high and low concentrations, it was necessary to 
construct two standard curves covering the concentration ranges ofO to 1.0 ^ig/ml and 
0 to 10.0 ^ig/ml, respectively. 
The calibration curves were constructed by spiking various amounts of p-C\ 
AAP (10 \xg/m\ or 100 ^ig/ml in methanol) into control blank rat blood (250 ^il). For 
the low range calibration curve, four concentrations (0.2, 0.4, 0.6 and 1.0 ^ig/ml) were 
made and each was measured thrice (n=3). For the high range calibration curve, 
solutions of four different concentrations (2.0, 4.0, 6.0 and 10.0 ^ig/ml) were prepared 
and each solution was measured thrice (n=3). The internal standard, p-Cl AZI (100 i^l 
of 10 ^ig/ml in methanol for low range standard curve, or 100 i^l of 100 ^g/ml in 
methanol for the high range standard curve), was added to the blood mixture with the 
appropriate amounts of the Delory and King's carbonate-bicarbonate buffer (pH 10.0) 
and made up to a total volume of 1 ml prior to the solid phase extraction as described 
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in section 2.3.3. HPLC was conducted under the conditions mentioned in section 2.3.1 
with UV detection at 254 nm. Peak area ratios of drug / internal standard 0^-Cl 
AAP/AZI-C1) were then plotted against concentrations of>-Cl AAP. 
^ 
2.3.5 Construction of Calibration Curves for p-ClAAP in Rat Urine 
Calibration curves for p-C\ AAP in urine were constructed in essentially the 
same way as that for p-C\ AAP in blood. Varying amounts of p-C\ AAP (100 ^ig/ml 
or 1000 ^ig/ml in methanol) were spiked into control rat urine (0.5 ml) to produce 
concentrations in the ranges of 0-10 ^ig/ml and 0-100 ^ig/ml, together with a fixed 
amount ofthe internal standard, p-C\ AZI (100 i^l of 100 ^ig/ml in methanol for the 
low range standard curve, or 100 i^l of 1000 ^ig/ml in methanol for the high range 
standard curve). For the low range calibration curve, five points of concentration 0.0, 
2.0, 4.0, 6.0 and 10.0 ^ig/ml were made and each point was detected in triplicate 
(n=3). For the high range calibration curve, the five points ofconcentration 10.0, 20.0, 
40.0, 60.0 and 100.0 ^ig/ml were made and again each point was detected in triplicate 
(n=3). Again, the final volume of the urine mixture was adjusted to 1 ml with Delory 
and King's carbonate-bicarbonate buffer (pH 10.0) and subjected to extraction as 
described in section 2.3.3. 
2.3.6 Accuracy and Precision in the Quantitation of p-Cl AAP in Biological Fluids 
Intra- and inter-day assay variability was investigated to determine the 
accuracy and precision of the developed assay. Known amounts of p-C\ AAP were 
spiked into blank blood (0.25 ml) and urine (0.5 ml) to produce the final 
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concentrations in the following two ranges for each blank: 0.2 - 0.8 and 2 - 4 ^ig/ml 
for blood; 2.0 - 8.0 and 25.0 - 75.0 ^ig/ml for urine. The internal standard, p-Cl AZI 
. was spiked (100 i^l of 10 ^ig/ml and 100 ^ig/ml for both low and high levels in blood 
respectively; and 100 i^l of 100 ^ig/ml and 1000 ^ig/ml for both low and high levels in 
urine respectively) into the mixtures. The final volume of the mixtures was adjusted 
with the Delory and King's buffer (pH 10.0) to 1 ml before the solid phase extraction 
as mentioned in section 2.3.3. The resulting sample mixtures were analyzed on the 
same day and three separate days respectively for intra- and inter-day variability. The 
percentage difference between the amount of p-C\ AAP determined and the amount 
spiked was taken as a measure of accuracy and the coefficient ofvariation (C.V.) as a 
measure of assay precision. 
2.4 PRELIMINARY PHARMACOKINETICS OF p-C\ AAP FOLLOWING 
INTRAVENOUS ADMINISTRATION 
2.4.1 Cannulae Preparation 
A knot was made onto the cannula by introducing the PE tubing with larger 
diameter onto the smaller diameter PE tubing. 
2.4.2 Dosage 
p-C\ AAP was dissolved into 50% p-cyclodextrin. A single dose of p-C\ AAP 
(20 mg/kg) was administered intravenously. 
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2.4.3 Animal Surgery and Sample Collection 
Rats were surgically prepared 24 hours before administration of the p-C\ AAP. 
Cannulae were implanted into the jugular vein under light anaesthesia by ether. For 
X 
the insertion ofthejugular vein cannula, a longitudinal incision (approximately 2 cm) 
was made on the skin above the vein. The tissues surrounding the vein were cleared to 
expose approximately 1 cm of the vein itself. The ends of the exposed vein were 
secured with loose ligatures and a small puncture was made on the wall ofthe vein by 
the needle (23 G). The prepared cannula was attached to a 1 ml syringe charged with 
heparin and inserted into the vein in the direction of the heart to a distance of about 2 
cm. The ligatures were then secured tightly in front and at the back of the knot to 
ensure the cannula remained in place upon recovery of the animal. Heparined saline 
(200 i^l, 100 I.U./ml) was administered through the cannula to prevent the blocking of 
the tube by the coagulation of the blood. The syringe was disconnected from the 
cannula and replaced with a 1 cm light stainless steel pin and the cannula exteriorised 
on the back of the neck in the intracapsular region. The surgical incisions were then 
closed using cotton sutures and the wound swabbed with ethanol-dipped cotton wool. 
The carotid artery was cannulated in a similar manner, with a ventral mid 
cervical incision made to expose the carotid artery. The carotid artery is found in a 
much deeper position than the jugular vein and in close proximity to the vagus nerve. 
The other important difference to vein cannulation is that the upper ligature on the 
artery was made secure before making an incision to stop blood from being pumped 
out under the great pressure that exists in the artery. Again the cannula was 
exteriorised and the incision site on the animal front closed with sutures. The 
operation lasted approximately 30 minutes. 
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Cannulated rats were allowed to recover ovemight before administration of;?-
C1 AAP. Drug (20 mg/kg) were administered via thejugular cannulae and serial blood 
samples were collected at appropriate time intervals (pre-dosed, and 5, 15, 30 and 45 
min., 1, 2, 3, 4 and 5 hours post-dosed). The pH of the blood sample taken (250 i^l) 
were immediately raised by the addition of Delory and King's carbonate-bicarbonate 
buffer (pH 10.0) to prevent any possible ex vivo alterations in drug concentration. 
Samples were stored at 4 � C before solid phase extraction as previously described and 
analysis by HPLC (section 2.3). 
2.4.4 Pharmacokinetic Calculations 
Pharmacokinetic parameters were determined by noncompartmental 
pharmacokinetic data analysis, using the PK Solutions 2.0 software (Summit Research 
Services, Ashland, U.S.A.). The equations used were shown below: 
Elimination rate constant (kg) = -2.303 x slope 
Half-life = 0 . 6 9 3 / k e 
Area Under Curve (AUC) = AUC(o. t) + [last drug concentration] / ke 
Volume of distribution (Vd) = Dose administered / (kg x AUC) 
Clearance (CL) 二 Dose administered / AUC 
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2.5 URINARY METABOLIC STUDIES OFp-C\ AAP 
2.5.1 Animal Treatment and Urine Collection %. 
Male Sprague-Dawley rats (200 - 250 g) were divided into three groups with 
five rats for each group. Rats in the first group were pretreated with phenobarbitone 
(80 mg/kg/day，intra-peritoneal) for three consecutive days prior to the administration 
of p-C\ AAP. The rats in the first phenobarbitone pretreated group and the second 
groups without phenobarbitone pretreatment were administered p-C\ AAP intra-
peritoneally with a single bolus dose (100 mg/kg). Rats in the third group (control 
group) were administered with the vehicle, 50 % p_cyclodextrin, alone. All the rats in 
these three groups were placed in individual perspex metabolic cages with free access 
to food and water. Urine free of faeces was collected for 0-24 hr and 24-48 hr 
respectively. In order to avoid possible degradation of excreted parent drug and 
metabolites, the urine was immediately frozen by collecting into tubes immersed in 
liquid nitrogen. The collected urine sample was stored at -20 °C until analysis. 
2.5.2 Deconjugation Assay 
The urine samples collected were subjected to deconjugation using P_ 
glucuronidase and p-glucuronidase / arylsulphatase enzymes, separately. These 
enzymes hydrolyze glucuronide and/or sulphate conjugates into corresponding phase I 
metabolites respectively. 
Three 1 ml aliquots of each urine sample were taken. To the first aliquot was 
added P-glucuronidase (1000 units) in acetate buffer (pH 5.0; 1 ml); to the second, P_ 
glucuronidase / Arylsulphatase (1000 units each) in acetate buffer (pH 5.0; 1 ml); and 
Chapter Two 25. 
to the third, buffer alone (pH 5.0; 1 ml). All sample mixtures were then incubated 
ovemight in a water bath at 37 °C. The samples were subjected to solid phase 
� extraction and then analyzed by HPLC as mentioned in section 2.3.3 and below. 
2.5.3 Non-deconjugated Urine Sample Treatment 
5 ml of urine sample was taken and extracted by solid phase extraction and 
analyzed by HPLC as mentioned in section 2.3. 
2.5.4 Separation of Metabolites by HPL C 
The samples were dried and subjected to HPLC analysis after reconstitution 
with the mobile phase as mentioned in section 2.3. Metabolites (indicated by 
characteristic peaks in the chromatogram) were collected as different fractions after 
passage through an Alltima C18 100A 5U (250 x 10 mm) column (Alltech Associates, 
Inc., USA). An ODS guard column (Alltech Associates, Inc., USA) was used to 
protect the preparative column. The apparatus and conditions were similar to those 
mentioned in section 2.3.1 except the flow rate was increased to 4 ml/min. The 
fractions were dried and stored at -80 °C until analysis. 
2.5.5 Identification of Metabolites by LC/MS 
The metabolite in each fraction was analyzed by liquid chromatography/mass 
spectrometry (LC/MS). The LC analysis employed a HP 1090 Liquid Chromatograph 
(Hewlett Packard Company, U.S.A.) and similar HPLC conditions to those in section 
2.3. For the MS analysis, a triple-stage quadrupole mass spectrometer (Finnigan MAT 
TSQ 7000 System, Germany) with atmospheric pressure chemical ionization (APCI) 
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method were employed for a direct probe MS analysis, a quadmpole ion trap mass 
spectrometer (Finnigan MAT GCQ DPC System, Germany) with chemical ionization 
(CI) and electron impact ionization (E.I.) were performed. In APCI mode, the 
ionization current used was 5 i^A and the ion polarity selected were both positive and 
negative. The capillary and vaporizer temperature was 150 and 400 °C, respectively. 
Nitrogen was used as the sheath gas and the pressure was 40 psi. The electron 
multiplier voltage was 1200 V. The range of mass scanned was 110 to 500 a.m.u. and 
the scan time was 1 second. For the MS/MS experiment, the range of mass scanned 
was 0 to 400 a.m.u. The scan time was 0.5 second. The collision gas used was argon 
and the gas pressure and energy was 0.2 Pa and 5-40 eV, respectively. In EI mode, the 
ionization voltage was -20 eV and the ion source temperature was 190 °C. The 
electron multiplier voltage was 1200 V. The scanned mass range was 10 - 500 a.m.u. 
and the scan time was 0.5 second. For CI-MS was employed in the MS/MS analysis 
and the mass range scanned was 0 - 400 a.m.u. and the scan time was 0.5 second. The 
collision gas was helium. The gas pressure and energy were 0.1 Pa and 30 eV, 
respectively. 
2.5.6 Quantitative Analysis 
Prior to solid phase extraction, the urine samples were spiked with 10 jiig and 
100 i^g of internal standard, p-C\ AZI for the deconjugation and non-deconjugation 
treatment of samples respectively. The extracts from solid phase extraction (section 
2.3.3) were analyzed by HPLC as described in section 2.3. 
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The peak area ratio ofthe p-Cl AAP to the intemal standard was recorded, and 
the amount ofthe p-C\ AAP in urine extracts was determined by using the calibration 
curves constructed as mentioned in section 2.3. 
� . 
Since there are no authentic samples for the construction of calibration curves 
of the respective metabolites, relative amount of the metabolites was stated in the 
whole study. The peak area ratio obtained for the metabolite to the intemal standard, 
p-CX AZI, was recorded and the peak area ratio to those metabolites appeared as phase 
I metabolites was considered to be 100 %. The amounts of the glucuronide and 
sulphate conjugates of the metabolites were determined as the percentage of their 
respective phase I metabolites, i.e., the ratio ofthe peak area ratio of the glucuronide 
or sulphate conjugates to the peak area ratio oftheir phase I metabolite. 
For those metabolites which did not appear as phase I metabolites, those peak 
area ratios of the glucuronide conjugate (to the peak area of the intemal standard) 
were considered as 100 %. For those sulphate-conjugated metabolites, the relative 
amounts were determined as the percentage of its respective glucuronide conjugates, 
as mentioned previously. 
The amounts of the glucuronide conjugates of the metabolites were calculated 
by subtracting the amount of phase I metabolite from those of the amount found after 
P-glucuronidase deconjugation. The relative amounts of the sulphate conjugates ofthe 
metabolites were calculated by subtracting the amounts of phase I metabolite and 
glucuronide conjugate of the metabolite from those of the amount found after p_ 
glucuronidase / arylsulphatase deconjugation. 
When comparing the effect on the relative amount of each metabolite between 
the phenobarbitone and non-phenobarbitone pretreatment, those amounts of the 
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metabolites from non-phenobarbitone pretreated rats were considered as 100 %. The 
amounts ofthose metabolites excreted from phenobarbitone pretreated rats were taken 
� as the percentage of the amounts of those from the non-phenobarbitone pretreated 
rats. 
2.5.7 Preparation of the authentic P-amino alcohol 
50 mg ofADD17014 was dissolved in 2.4 ml water. Then, 40 i^l hydrochloric 
acid (1 M) was added in dropwise. The reaction mixture was stood at room 
temperature with continued stirring for 7 hours. The reaction was stopped by addition 
of 650 i^l sodium hydroxide (1 M). The P-amino alcohol was extracted by diethyl 
ether and any residual water was removed by anhydrous magnesium sulphate. The P_ 
amino alcohol was purified by HPLC using Alltima C18 100A 5U (250 x 10 mm) 
column (Alltech Associates, Inc., USA) with the mobile phase consisting of the 
mixture of methanol, acetonitrile and water in the ratio of 25 : 25 : 50 (together with 
20 i^l of diethylamine per 100 ml ofmobile phase). The identity of obtained P-amino 
alcohol was confirmed by HPLC/MS/MS. 
2.6 STATISTICAL ANALYSIS 
All results were expressed as means 士 standard deviations. Analysis of 
variance (ANOVA, single factor) was used to compare results between different 
groups. A probability (p) ofless than 0.05 was considered statistically significant. 
� 
Chapter Three 
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3 • 1 PREFORMULATION STUDIES ON AMINOALKYLPYRIDINES 
� 3.1.1 PARTITION COEFFICIENT (K: ) 
The calibration curves for the determination of partition coefficients of the 
various AAPs were constructed and Table 3.1.1 shows the equations computed for the 
calibration plots. For all calibration curves there was excellent linearity (linear 
correlation coefficient > 0.999; n = 5; P<0.05). Each data point was determined four 
times. 
Table 3.1.1 Linear equations computed for the calibration plots for the partition coefficient 
determination of various aminoalkylpyridines. 
AAP Equation R^ 
^ y = 0.0316x + 0.0024 0.9999~~ 
7 i a y = 0.0495 x-0.0019 0.9998~" 
;7-Br y = 0.0481 x+ lE-05 1 
pCH3 y = 0.0478 x + 0.0006 1 
m-CF3 y = 0.024 X - 0.0028 0.9998~~ 
The partition coefficients obtained for the aminoalkylpyridines are shown in 
Table 3.1.2. While the p-F, p-Cl, p-Bv, and j9-CH3 AAPs showed no statistically 
significant differences in their Kw, the m - C F 3 AAP exhibited a much lower K°w 
(37.23 土 1.2). It may be explained by increased ionization of the m - C F 3 substituted 
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aniline resulting in a greater fraction of the compound being partitioned into the 
aqueous phase. 
� . 
Table 3.1.2 Preformulation parameters of aminoalkylpyridines. 
AAP Partition M ? Melting Temperature Xi? A ? 
Coefficient (kJ/mol) Temp. (°C) Range (°C) (kJ/mol) (J/mol/K) 
~J^ 7 1 . 9 6 + 7 . 2 ~ ~ 2 5 . 0 6 ± 1 . 4 ~ ~ 8 4 . 0 5 士 0 . 7 ~ ~ 8 2 . 4 ~ 87.8"""19.0i0.6 5 3 . 6 ± 1 . 6 
~ ^ \ 75.61士1.8~~23.88 i 2 . 4 ~ ~ 1 0 5 . 1 i 0 . 6 103.4- 108.3 21.5±0.9 57.0 + 2.4 
p-Br 82.29 ± 6.0~~25.02 + 1.4~~107.5 ± 0.3~~107.9- 110.5 21.7±0.7 57.1 ±1.8 
, • ‘ ,.":稱::.丨 . 
/7-CH3 7 3 . 7 2 ± 4 . 5 “ “ 2 0 . 2 4 t l . l ~ ~ 9 4 . 0 土 0.2 94.4 �97 .0~~~23 .4 t l . 7~~63 .7±4 .6 
m-CF3~~"37.23 ±1.2““34.76±1.8"““150.8±0.3““151.0- 153.3 33.8 ± 1.9 79 .8 t4 .5 
3.12 AQUEOUS SOLUBILITY 
The calibration curves used for the determination of aqueous solubility of the 
various AAPs were constructed and Table 3.1.3 shows the equation computed for the 
calibration plots of them. For all calibration curves there was excellent linearity (r > 
0.999; P < 0.05; n = 4) (each data point was measured four times). 
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Table 3.1.3 Linear equations computed for the calibration plots for the aqueous solubility 
determination of various aminoalkylpyridines. 
1 2 AAP Equation R 
X __^_^^_^^^^^^__ 
^ y -0 .0341 x - 0 . 0 0 2 2 ^ 0.9998 
p-C\ y = 0.0623 x - 0.0042 0.9999 
p-Bv y = 0.0561 x + 0.0018 0 .9998^ 
j9-CH3 y = 0 . 0 4 9 x - 2 x l 0 - ' ' 0.9997 
m-CF3 y = 0.0162x-0.0014 0.9991"~ 
The solubilities of various AAPs in water increased with an increase in 
temperature (Table 3.1.4 and Figure 3.1.1). In addition, the solubilities depended on 
the substitutent on the benzene ring of the AAPs, and decreased in the following 
order: p-¥ AAP > j!>CH3 AAP > p-C\ AAP > ^ B r AAP > m-CF3 AAP. 
Table 3.1.4 Aqueous solubilities of various aminoalkylpyridines at different temperatures. 
‘ Types ofAAP 
Temp. (�C) ^ ^ /?-Br p-CR^ m-CV^ 
Concentration (M), x 10'^  
S 204.4 + 2.4 33.8 + 1.2 12.4i0.1 86.7±2.2 5.83 ±0.4 
30 221.8±L8 3 4 . 9 ± 0 . 7 1 3 . 1 ± 0 . 1 8 7 . 7士 1.3 6.06 土 0.2 
f j 282.6±5.4 55.2 + 5.9 18.3 ±0.3 112.8±2.2 8.91±0.5 
45 330.9±5.1 57.6±3.8 22.4±0.3 135.3 11.0 12.7±0.6 
5 0 4 2 8 . 7士 2 . 7 66.2 土 6.4 24.5 ± 0.7 1 5 3 . 5 ± 4 . 9 1 6 . 2 ± 0 . 6 
^ 506.1 ±4.2 75.6±4.5 31.5±0.6 178.7±6.8 18.4±1.2 
^ 5 6 9 . 2 ± 9 . 2 96.7 士 8.7 3 4 . 4 ± 1 . 2 1 9 2 . 0 ± 16.6 24.1 ± 0 . 4 
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Figure 3.1.1 Plot o f aqueous solubilities of AAPs against temperature (°C). 
The soluMlity data were analyzed using the van't Ho f f equation, and the associated 
plots and regression equations are shown in Figure 3.1.2. 
The van't Hof fp lo ts for the various AAPs displayed good linearity (r = 0.95 -
0.99; n = 7; p < 0.05), showing that the van't Ho f f equation was obeyed by all the 
AAPs. The apparent molar enthalpy of solution, AH', o f each AAP was determined 
from the slope o f the plot, and the values are presented in Table 3.1.2. There were no 
statistically significant differences in AH' among the three halogen substituted AAPs. 
The p-CU3 AAP had a lower AH' (20.24 土 1.1 kJ/mol) while the AH' of the m-CF3 
AAP (34.76 士 1.8 kJ/mol) was the highest of all the five AAPs. As can be seen later, 
the change in the enthalpy of fusion, AH ,^ of these AAPs parallel closely that of the 
AR\ 
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Figure 3.1.2 Van't Hoff plots on the saturated aqueous concentration of AAPs. 
The AH^ values are similar in magnitude to the AH' (being lower by 1 - 6 kJ/mol), 
suggesting that the aqueous solubilities of the AAPs are governed predominantly by 
solute-solute interaction in the solid state. This argument is based on the following 
thermodynamic considerations. 
The dissolution ofa solid in a solvent can be viewed as being equivalent to the 
melting of the solid (break down of solute-solute interaction) followed by mixing of 
the resulting liquid solute with the solvent (establishment of solute-solvent 
interaction). The enthalpy of solution, AH' ,of the solid is therefore given by 
AH% = Arfx + AHn,ix 
where AH^ 丁 is the enthalpy of fusion at the absolute temperature T of the solution, 
which is invariably below the normal melting point Tm of the solid, and AHmix is the 
enthalpy of liquid-liquid mixing. 
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AH^ is positive (i.e. endothermic transition) since energy is required to break 
down the solute-solute interaction to effect melting while AHmix is generally negative 
, (i.e. exothermic transition) if there exists an affinity between the solute and the 
solvent. 
In present study, the AH^ measured was that at the melting point. Since the 
quantitative effect of temperature on AH^ is not known, it is not possible to estimate 
AH^ at the absolute temperature T of the solution. However, if it is assumed that the 
effect of temperature on AH^for the five AAPs is closely similar, the contribution of 
AH^ (i.e. solute-solute interaction) to the AH' term would still be predominant 
compared with that of the AHmix (solute-solvent interaction). The dominant effect of 
the solute-solute interaction (i.e. crystal structure) on solubility has been further 
substantiated by the good correlation between the aqueous solubilities and melting 
points of the AAPs (see later discussion). 
3.1.3 THERMAL ANALYSIS 
The thermograms ofthe DSC studies on AAPs (Figure 3.1.3 - 3.1.7) displayed 
single sharp endotherms corresponding to melting with flat baseline at temperature 
above melting, suggesting that (a) the AAPs do not contain any solvent of 
crystallization, and (b) the AAPs are thermostable. However, the predecessor 
anticonvulsants, triazolines, exhibited decomposition (data not shown) as the 
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In this study, the melting point, the melting temperature range, AH and AS of 
AAPs were also determined. They are tabulated in Table 3.1.2. The melting point of 
� the three halogen-substituted AAPs increased in the following order: p-V AAP <p-C\ 
AAP < p-Br AAP. Interestingly, there were only small (statistically insignificant) 
differences of the AH^ and AS^  among these three AAPs. The aqueous solubilities of 
the AAPs were found to be related to their melting points; the higher the melting point 
of the AAPs, the lower was the solubility. By plotting the aqueous solubilities of the 
AAPs (on logarithm scale) against the melting temperature (Yamaoka, 1983) in 
Figure 3.1.8, a significant linear correlation (r^ 二 0.8008; r = 0.895; n = 5; p < 0.05) 
was obtained. This suggested that the solubilities of AAPs was governed by the 
solute-solute interaction in the crystal structure, as alluded to earlier. 
_ _ ___    
-5.0 1  
-5.5 -
• > 
1 -6.0 - ^ ^ - - ^ ^ 
1 ^ " " ^ ^ ^ ^ R2 = 0.8008 
2 -6.5 ^ ^ \ ^ 
I • ^ " ^ \ ^ 
1 -7.0 - • ^ ^ - ^ ^ 
2 ^ ^ 
-7.5 -
-8.0 ^ 1 ^ 1 1 ‘ ‘ “ ‘ " ‘ 
70.0 80.0 90.0 100.0 110.0 120.0 130.0 140.0 150.0 160.0 
melting temperature (°C) 
Figure3.1.8 Plot of the log molar aqueous solubility of AAPs against the melting 
temperature in °C. 
Chapter Three 1^ 
From the plot, the data point for the m-CF3 member appears to deviate from the linear 
trend ofthose ofthe j^ara-substituted members, suggesting that the former may be an 
atypical observation (i.e. outlier). This is perhaps not unexpected since the CF3 
� -
member is me^-substituted while the rest of the AAPs are j^ara-substituted. 
Exclusion ofthe m-CF3 AAP from the plot afforded an r^  = 0.93 (r = 0.96; n = 4; p < 
0.05), an improvement of 13 % in terms of predictability. 
In general, all the physical properties of AAPs were shown to depend on the 
chemical structure of the compounds. 
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3.2 DEVELOPMENT OF A HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHIC ASSAY FOR p-C\ AMINOALKYLPYRIDINE 
^ 
3.2.1 SOLID PHASE EXTRACTION 
The solid phase extraction technique allowed separation ofthe parent drug and 
its putative metabolites from endogenous interfering substances. The HPLC 
chromatograms ofthe extracts ofblank blood and urine containing, p-C\ AAP (parent 
drug),p-Cl AZI (intemal standard) and the putative metabolite of p-Cl AAP, P-amino 
alcohol (p-AA, putative metabolite) are shown in Figure 3.2.1. From the 
chromatograms, retention times for the p-C\ AAP, P-AA and p-Cl AZI peaks, were 
found to be 7.8, 4.7 and 9.3 minutes, respectively. A good separation of these 
compounds with baseline separation was obtained. Very few interfering peaks at the 
retention times ofthe drug and the intemal standard were observed, indicating that the 
solid phase extraction procedure is effective for removing endogenous compounds in 
the blood and urine samples. 
3.2.2 CONSTRUCTION OF CALIBRATION CURVES FOR p-Cl AAP IN THE 
RAT BLOOD 
Table 3.2.1 shows the peak area ratios of p-Cl AAP to p-C\ AZI, an intemal 
standard, for both lower and higher concentration ranges in rat blood, and the 
corresponding calibration plots are shown in Figure 3.2.2 and 3.2.3. For both ranges 
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Table 3.2.1 Peak area ratios found in the construction of calibration curves f0r;7-Cl AAP in 
rat blood. 
Concentration (^ig/ml) Peak Area Ratio * C.V. (%) ** 
、， 
Low range ( y = 2.191x - 0.1568，R^ 二 0.9991，mean C.V. = 5.58 % ) 
0 0 -
0 . 2 0.30士0.01 3.3 
0.4 0.72 土 0.03 4.2 
0.6 1.13士0.03 2.6 
1.0 2.05±0.25 12.2 
High range ( y = 0.1672x - 0.0355, R^ 二 0.9973, mean C.V. = 3.65 %) 
0 0 -
2.0 0.28土0.01 3 . 6 
4 . 0 0 . 6 2 士 0 . 0 1 1.6 
6.0 1.01±0.02 2.0 
10.0 1.62±0.12 7.4 
* Mean 土 s.d. ( n = 3 ) 
** C.V. (%) = (s.d. / mean value) x 100 % 
2.5 n — 
2 y = 2.191x-0.1568 .• 
2 - R2 = 0.9991 ^ ^ ^ ^ ^ ” 
i 15 ^ ^ ^ 
w ^---<r 
I 1 ^ ^ ^ 
I 0.5 - ^ ^ ^ ^ 
^ o U ^ 
-0.5 H 1 1 1 ‘ 
0 0.2 0.4 0.6 0.8 1 
[p-CI AAP] (^ig/ml) 
Figure 3.2.2 Calibration curve in the range 0-1.0 ^ig/ml for j^-Cl AAP in rat blood. 
Chapter Three 1^ 
2  
1.8 -
1.6 - ^ ^ ^ 
- o 14 y = 0.1672x-0.0355 ^ ^ 
•I i:2_ R2 = 0.9973 ^ ^ ^ 1 1 ^ ^ 
^ 0 8 ^ ^ ^ 
2 0.6 - ^ ^ 
“ � 4 ^ ^ ^ 
0.2 ^ ^ 0 ^ ^ ^ 1 1 1— ‘ 
_0.2 i) 2 A 6- 8 10 
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Figure 3.2.3 Calibration curve in the range 0-10.0 fig/ml for p-Cl AAP in rat blood 
3.2.3 CONSTRUCTION OF CALIBRATION CURVES FOR p-Cl AAP ES[ THE 
RAT URES[E 
The peak area ratios of p-Cl AAP to j?-Cl AZI for both lower and higher 
concentration ranges in rat urine are shown in Table 3.2.2, and the associated 
calibration curves are shown in Figure 3.2.4 and 3.2.5. The plot was linear over the 
high and low concentration ranges (r > 0.98; n = 4; p < 0.05) (each point was 
measured in triplicate). 
A large deviation might result at two extremities of the calibration curve. High 
and low concentration ranges ofcalibration curves for p-Cl AAP in both rat blood and 
urine were constructed to ensure a more reliable and accurate quantitative analysis of 
p-Cl AAP in bio-fluid within these concentration ranges. 
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Table 3.2.2 Peak area ratios found in the construction of calibration curves for p-C\ AAP in 
rat urine. 
. Concentration (^ig/ml) Peak Area Ratio * C.V. (%) ** 
~~Low range ( y = 0.1864x - 0.1081, R' = 0.9995，mean C.V. = 2.1 % )~~ 
0 0 -
2.0 0.28士0.01 3.6 
4.0 0.62±0.02 3.2 
6 . 0 1 . 0 1 土 0 . 0 1 1.0 
10.0 1.76±0.01 0.6 
High range ( y 二 0.0128x + 0.0547, R^ = 0.9745, mean C.V. = 8.08 %) 
0 0 -
2.0 0.26±0.01 3.8 
4 . 0 0 . 5 7 土 0 . 0 1 1.8 
6.0 0.92±0.03 3.3 
10.0 1.28±0.3 23.4 
* Mean 士 s.d. ( n = 3 ) 
** C.V. (%) = (s.d. / mean value) x 100 % 
2 -^  ~" 
15- y = 0.1864x-0.1081 ^ ^ ^ ^ ^ 
•2 R2 = 0.9995 ^ ^ ^ ^ 
re ^ ^ ^ DH 1 ^ ^ ^ « ^ ^ 
I ^ ^ ^ 
老 0 5 ^ ^ 0) ^^^^^ 
^ o t ^ ^ 
-0.5 \ 1 1 1 1 1 1 1 I ‘ 
0 1 2 3 4 5 6 7 8 9 10 
Lo-CI AAP] (^g/ml) 
Figure 3.2.4 Calibration curve in the range 0-10 ^ig/ml forp-C\ AAP in rat urine. 
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% 1 - y = 0.0128x + 0.0547 ^ ^ ^ 
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0.4 ^ ^ ^ - ^ ^ ^ 
0 2 J / - - ^ 
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Figure 3.2.5 Calibration curve in the range 0-100 ^ig/ml for p-Cl AAP in rat urine 
3.2.4 ACCURACY AND PRECISION ][N THE QUANTITATION OF p-Cl AAP 
IN THE BIOLOGICAL SAMPLES 
The developed assay was reproducible at both low and high concentrations 
with overall intra- and inter-day variations ofless than 12.5% and 17.5%, respectively 
(as shown in Table 3.2.3). The accuracy of the assay was within a range of 83 to 98% 
for blood and 86 to 99% for urine samples. 
In addition, the stability of p-Cl AAP in rat blood and urine, its recovery and 
limit of detection were determined by our research group (Lin, et al. 1998). It was 
found that there was no significant change in the concentration of p-C\ AAP in both 
blood and urine after prolonged storage at 4°C for at least 3 months, indicating that it 
is highly stable in both rat blood and urine. 
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Table 3.2.3 Intra- and inter-day variability for the assay of>-Cl AAP spiked in rat blood 
and urine. 
� Concentration Intra-day Inter-day 
(昭/ml) 
Spiked Found C.V. Accuracy Found C.V. Accuracy 
(^ig/ml) (%) (%) (^g/ml) (%) (%) 
Blood (n=3) 
0 ^ 0.18 + 0.01 ~ ~ ^ ~ ~ " " " i ^ ~ ~ | 0 . 2 3 t 0 . 0 4 | 17.4 ~ ~ K o ^ 
^ 0.67 士 0.03 ^ r ^ 0.87 + 0.09 10.6 8.8 
^ 1.73i0.17 ^ 13：5 2.22 + 0 . 3 5 ~ ~ ~ ^ H ^ ^ 
4^0 3 .92i0 .48 ^ ^ 4.34±0.56 12.9 8.5 
Urine (n=3) 
^ 2.10 + 0.03 “ “ L 7 “ “ ~ ~ 5 ^ ~ ~ ~ | 2 . 2 8 t 0 . 3 2 | 14.0 ~ ~ H ^ O ~ ~ 
^ 7.74±0.14 L8 ^ 8.10±0.56 6.9 1.3 
K 0 22.6+ 1.19 ^ ^ 2 4 . 2 t l . 7 8 ~ ~ ~ ^ ^ ~ ^ 
^ 81.2±4.44 ^ ^ 75.3 + 1.64~~"2.2 0.4 
C.V. (o/o) = (standard deviation/mean) x 100% 
Accuracy (%) 二 [(mean measured conc. - spiked conc.) / spiked conc.] x 100% 
The extraction recovery of p-Cl AAP from both blood and urine samples was 92 士 
3.0% and the limit of detection for this drug was 100 ng/ml in both urine and blood, 
respectively. A simple, sensitive and specific HPLC assay has been developed for the 
analysis of this novel aminoalkylpyridine anticonvulsant, p-Cl AAP, in rat biofluids 
which has been fully validated. This HPLC method allows the quantitative analysis of 
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p-C\ AAP in rat bio-fluids, and is useful for studying the metabolic and 
pharmacokinetic profiles of this novel anticonvulsant. 
� Since the preliminary metabolic studies in rats failed to show the presence of 
3-AA (the postulated active metabolite of p-C\ AAP), HPLC quantitation of this 
putative metabolite was not necessary and thus not reported here. 
HPLC has many advantages over gas chromatography quantitatively and 
qualitatively. In gas chromatography, the solute must be volatile and thermally stable, 
whereas in liquid chromatography, high molecular weight compounds and those that 
are thermally labile, polar or non-volatile can be analyzed. 
Since our p-C\ AAP is not volatile and only heat stable up to 250 °C as was 
described in the previous section, the detection of this novel anticonvulsant by HPLC 
is preferable. 
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3.3 PRELIMINARY PHARMACOKINETICS OF p-C\ AAP FOLLOWING 
INTRAVENOUS ADMINISTRATION 
^ 
The concentrations of p-Cl AAP in blood as a function of time after single 
intravenous (i.v.) bolus administration of20 mg/kg is shown in Table 3.3.1. The blood 
concentration-time curve is presented in Figures 3.3.1. The pharmacokinetic 
parameters are given in Table 3.3.2. 
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Pharmacokinetic studies onp-CI AAP (i.v.) 
5 n  
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Figure3.3.1 Blood concentration-time profiles of p-Cl AAP after single i.v. bolus 
administration to male Sprague-Dawley rats (20 mg/kg) (n = 5). 
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Figure 3.3.2 Log concentration of p-Cl AAP against time. 
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Table 3.3.2 Pharmacokinetic parameters ofp-C\ AAP after intravenous administration 
(20 mg/kg). 
Pharmacokinetic parameters 
� Elimination rate (hf^) 0.14 士 0.04 
Elimination half life (hr) 5.0 土 0.9 
Distribution rate (hf^) 0.49 土 0.2 
Distribution half life (hr) 2.34 士 1.0 
Area Under Curve (AUC) (^ig/ml.hr) 11.84 土 1.7 
Volume ofdistribution (Vd) (L/kg) 12.71 士 4.6 
Clearance (CL) (ml/hr) 1779.4 土 315 
The pharmacokinetic data for the intravenous single bolus administration 
showed a bi-exponential decline in the blood concentration of p-C\ AAP, 
characteristic of a two-compartmental model (Figure 3.3.2). The area under curve 
(AUC) was 11.84 士 1.7 ^ig/ml.hr. The volume of distribution (Vd) was 12.71 土 4.6 L, 
indicating extensive extravascular distribution. The clearance (CL) was 1779.4 士 315 
ml/hr. The elimination rate and half life of>-Cl AAP were 0.14 士 0.04/hr and 5.0 土 
0.9 hrs, respectively. The distribution rate and half-life were 0.49 土 0.2/hr and 2.34 土 
1.0 hrs, respectively. 
p-cyclodextrin was used as a vehicle for the administration of j^-Cl AAP to 
rats. It is enzymatically modified starches consisting of glucopyranose units in a ring 
system. It is crystalline, non-hygroscopic and feature a cylinder shaped, macro-ring 
structure with an internal axial cavity. The outer surface of cyclodextrin is hydrophilic 
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whilst the internal cavity is apolar. These properties make cyclodextrin a useful 
material for solubilizing lipophilic molecules. P-cyclodextrin is the most frequently 
� used vehicle because of its favourable cavity size for pharmaceutical compounds. In 
addition, no covalent binding is involved in solubilizing p-C\ AAP or other lipophilic 
compounds. As p-Cl AAP is a very lipophilic compound, P-cyclodextrin is a good 
vehicle for the administration of this novel anticonvulsant. 
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3.4 URINARY METABOLIC STUDIES OF p-C\ AAP 
� 3.4.1 QUALITATIVE STUDIES : IDENTIFICATION OF METABOLITES 
Typical HPLC chromatograms obtained from analysis ofurinary extracts pre-
and post-dose of>-Cl AAP are shown in Figure 3.4.1. Three major peaks are clearly 
shown in the post-dose sample which were absent in the pre-dose (control) urine 
sample. Figure 3.4.2 shows the HPLC chromatograms of the urine sample after p-
glucuronidase and aryl sulphatase / P-glucuronidase deconjugation. After p-
glucuronidase deconjugation (Figure 3.4.2 (A)) ofthe urine sample, three more peaks 
were found from the chromatograms. These additional peaks represented the 
glucuronide conjugates ofthe metabolites. These metabolites were formed due to the 
deconjugation by P-glucuronidase. After aryl-sulphatase / p-glucuronidase 
deconjugation (Figure 3.4.2 (B)) of the urine sample, another four peaks were 
observed from the chromatograms when compared with non-deconjugated urinary 
extract. These additional peaks represented either glucuronide and^or sulphate 
conjugates which were deconjugated by P-glucuronidase and/or aryl sulphatase / P_ 
glucuronidase, respectively. When compared with the samples deconjugated by p-
glucuronidase only, only one more peak was obtained (peak 7, Figure 3.4.2 (B)), 
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Based on the HPLC data (retention time) shown in Table 3.4.1, peaks 6 and 8 were/7-
C1 AAP and the internal standard, p-C\ AZI respectively. However, p-amino alcohol 
� was not formed as a urinary metabolite of p-C\ AAP by comparison of the HPLC 
prospects ofthe authentic standard (Table 3.4.1) 
Table3Al Retention times of p-C\ AAP, internal standard 0^-Cl AZI) and unknowns / 
putative metabolites, (n = 5) 
Compound Retention Time * (min.) 
Authentic samples 
p-amino alcohol (p-AA) 4.67 
p-C\ AAP 7.96 
p - a AZI 9.60 
Metabolites in urine of rats administrated with p-Cl AAP 
Peak 1 (metabolite-1) 3.91 
Peak 2 (metabolite-2) 4.25 
Peak 3 (metabolite-3) 4.50 
Peak4 (metabolite-4) 4.87 
Peak 5 (metabolite-5) 7.13 
Peak 6 Qp-Cl AAP) 7.88 
Peak7 (metabolite-6) 8.95 
Peak8 0>C1AZI) 9.49 
* HPLC conditions as outlined in section 2.3.1. 
In order to identify the chemical structures ofthe suspected metabolites, crude 
urinary extracts were analyzed by on-line HPLC/MS. However, since the utilized 
HPLC conditions failed to separate all analytes from various interfering compounds 
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present in the crude extract, the resulting mass spectra were not suitable for structural 
elucidation. Therefore, the crude extract after enzymatic deconjugation was further 
separated into four fractions by a preparative HPLC. The purified fractions were then 
analyzed by HPLC/MS/MS with atmospheric pressure chemical ionization (APCI) 
interface at both positive and negative ion modes. 
Figure 3.4.3 show the negative ion mass spectrum of the parent drug, p-C\ 
AAP. An intense peak at m/z 291 (Figure 3.4.3 (A)) and corresponding Cl-isotope 
peak at m/z 293 with about 30 % intensity. This confirmed that analyte contains C1 
atom. As demonstrated in the corresponding MS/MS spectrum (Figure 3.4.3 (B)), the 
ion at m/z 291 degraded readily to form a daughter ion at m/z 231，which represented 
the quasi-molecular ion of>-Cl AAP. The different of 60 mass units is due to the loss 
of acetic acid, which present in the mobile phase form adduct with the parent drug. 
Selecting ion ofm/z 231 for further MS/MS study (Figure 3.4.3 (C))，no characteristic 
fragmentations can be found. This indicated that the molecule of p-Cl AAP is very 
stable under the utilized conditions for APCI-MS and MS/MS analysis. 
As mentioned in the previous paragraph, chloride isotope peak with 2 mass 
units apart aids the identification of the chlorine-containing compounds. In the 
following, the elucidation of structure ofthe metabolites of p-Cl AAP assisted by the 
characteristic mass spectrum of chloride related compounds. However, in the MSMS 
spectrum, the daughter ions degraded from the selected mother ions will not exhibit 
the C1 isotope peak, because only the single ion containing the most abundant ^^ C1 
will be selected for collision-induced dissociation (CID). 
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Figure 3.4.3 Negative-ion mass spectra of p-C\ AAP, A) MS spectrum, B) MS/MS 
spectrum (select ion at m/z 291), C) MS/MS spectrum (select ion at m/z 231). 
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The MS and MS/MS spectra of p-Cl AAP demonstrated the formation of 
“solvent adduct", i.e. acetic acid adduct of>-Cl AAP. For the soft ionization, such as 
APCI and ESI, it is very common that compounds with a small molecule present in 
the mobile phase can interact with the analytes to form the "solvent adduct". As this 
adduct is not covalently bound compound, only small amount of energy can cause its 
dissociation. Therefore, a quasi-molecular ion can be easily yielded in the MS/MS 
spectrum with a suitable CID energy (Williams and Fleming, 1987). 
As shown in Figure 3.4.4, the total ion chromatogram obtained from 
HPLC/MS/MS analysis of fraction 1 exhibited two peaks, which were defined to be 
metabolite-1 and metabolite-2, respectively, by comparison of their retention times 
with those obtained in the HPLC-UV analysis as discussed in the section 2.3. For 
metabolite-1, the negative ion mass spectrum showed a quasi-molecular ion at m/z 
279 [M-1]"，together with a C1 isotope peak at m/z 281, indicating that it is a drug 
related metabolite (Figure 3.4.5 (A)), and its corresponding reconstructed ion 
chromatogram obtained by using selective ion monitoring (SIM) programmer also 
confirmed that only one metabolite contained such a molecular ion (Figure 3.4.4). 
Therefore, the molecular weight of metabolite-1 was determined to be 280 Da, 
indicating addition of three oxygen atoms in the parent p-C\ AAP. The MS result 
suggested that this analyte is an oxidized metabolite. Furthermore, using a CID energy 
of 30 eV, the negative-ion MS/MS spectrum of this metabolite did not show any 
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Figure 3.4.5 Negative-ion mass spectra of metabolite-1 from respective chromatograms of 
Figure 3.4.4. A) MS spectrum, B) MS/MS spectrum of metabolite-1. 
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In addition, a positive chemical ionization (CI) MS/MS of this metabolite using a 
direct probe insertion technique was also conducted. The resultant CI-MS/MS 
� spectrum did not show fragmentation again (not shown). These results suggested that 
metabolite-1 is relatively stable to CID, and thus this compound should have a general 
structure of C5H4N-CH(CH3)-NH-C6H5, similar to that of the parent p-C\ AAP. In 
APCI-MS/MS, phenolic groups are difficult to be dissociated (Herbert et al., 1967), 
while hydroxyl groups generally generate fragment ions with a loss of water, a 18 
mass units. Furthermore, in the case ofiV-oxide, a loss of 16 mass units corresponding 
to an oxygen atom is commonly observed (Herbert et al., 1967). Therefore, the 
oxidative sites are likely in the aromatic rings, i.e. three hydroxyl functional groups 
substituted in the aromatic rings. Thus, the structure of metabolite-1 has been 
tentatively identified as trihydroxylated p-C\ AAP, A^-[4-(2-hydroxychlorophenyl)]-l-
[4-(2,6-dihydroxypyridyl)]ethylamine (Figure 3.4.6). 
H O O H 
N > t ^ ^ C I 
/ � H 3 
H O 
Figure 3.4.6 Structure of metabolite-1, A^-[4-(2-hydroxychlorophenyl)]-l-[4-(2,6-
dihydroxypyridyl)] ethylamine. 
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The positions of three hydroxyl groups could not be assigned in the present study. 
However, it is likely that two hydroxyls are situated at 3 and 5 positions in the 
� pyridine ring and the third is at the 3 position in the benzene ring. 
Metabolite-1 was only found after glucuronidase and/or aryl-sulphatase 
deconjugation. Therefore, the identified urinary metabolite-1 is mainly in its 0-
glucuronide and 0-sulphate conjugates. However, whether or not all hydroxyl groups 
or only one of them were conjugated could not be determined in this study. In 
addition, arylamine sulphate might also form. Further studies involving the use of 
Nuclear Magnetic Resonance (NMR) and Infrared (IR) analysis are required for a 
definitive identification of this metabolite. 
The negative ion APCI-MS spectrum obtained from HPLC/MS/MS analysis 
ofthe second analyte, metabolite-2, in fraction 1 showed the highest mass ion at m/z 
307 with C1 isotope peak at m/z 309 (Figure 3.4.7 (A)). As demonstrated in the 
corresponding MS/MS spectrum (Figure 3.4.7 (B)), the ion at m/z 307 easily degraded 
to form a daughter ion at m/z 247, which represented the quasi-molecular ion of 
metabolite-2. Therefore, molecular weight of metabolite-2 was determined to be 248 
Da, and the ion at m/z 307 ([M + AcOH-l] ) was an acetic acid adduct of metabolite-
2. Compared with molecular weight of the parent ;7-Cl AAP (232 Da), metabolite-2 
has one more oxygen atom in the structure and should be the oxidized metabolite of 
p-Cl AAP. However, this metabolite is not the P-amino alcohol as its retention time 
does not match that of the authentic standard. 
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Figure 3.4.7 Negative-ion mass spectra of metabolite-2 from respective chromatograms of 
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Chapter Three 1^ 
Further MS/MS analysis of this metabolite did not produce other fragment ions, a 
direct probe CI-MS/MS analysis with a positive ion mode was performed. CI-MS/MS 
spectrum exhibited characteristic ions at m/z 122, the base peak, and other fragment 
ions at m/z 233, 219 and 127，respectively (Figure 3.4.8). Based on the fragment 
pattem, metabolite-2 was tentatively identified as A^-[4-(chorophenyl)]-l -hydroxyl-1 -
[4-(pyridyl)]ethylamine. The proposed structure of metabolite-2 is shown in Figure 
3.4.9 and mass fragment pathway in Figure 3.4.10. 
0 " + 1 " ^ ^ c i 
U CH3 ^ 
Figure 3.4.9 Structure of metabolite-2, 7V-[4-(chlorophenyl)]-l-hydroxy-1-[4-
(pyridyl)]ethylamine. 
As shown in Figure 3.4.10, the fragment ion at m!z 122 was generated via a loss o fa 
neutral molecular [HN-C6H4Cl + OH], which is favourable for carbinolamine moiety 
and could not be observed in the MS spectrum of the parent p-C\ AAP. The CI-
MS/MS spectrum also suggested that this oxidized metabolite should not be the 
aromatic ring hydroxylated 户-Cl AAP, since phenolic metabolites could not be 
fragmented as demonstrated in MS spectrum ofthe parent p-C\ AAP (Herbert et al., 
1967). Therefore, the hydroxyl group is most likely located at the a carbon atom, and 
the assigned structure was derived (Figure 3.4.9). 
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0 ~ ? 1 ^ ^ C I +H+ 
^ CH3 ^ 
、 ^ ^ ^ m/z 249 [M+1]+ 
N Q ~ ? = N H + H+ H+ 
^ ^ ^ CH3 / = x / “ • . f = \ 
m/z 122 (100%) V ^ d # ^ " V J ^ C I 
^ C H 3 
m/z 233 ^ + 
' Q ^ ^ " H - 0 " " 
m/z219 
Figure 3.4.10 Possible fragment pattem of metabolite-2 in positive ion CI-MS. 
Both phase I and phase II of this metabolite were found in the rat urine. For 
the phase II metabolite, the glucuronide and sulphate conjugates were all identified. 
The hydroxyl functional group should be a main site for 0-glucuronidation. Whilst, 
arylamine sulphation is most likely for sulphate conjugate. 
The total ion and reconstructed ion chromatograms obtained from 
HPLCMS/MS analysis of fraction 2 are shown in Figure 3.4.11. Two peaks 
































































































































































































































































































































































































































































































Chapter Three 1^ 
The negative APCI-MS spectrum of metabolite-3 showed an ion of the highest mass 
at m/z 325 with an appropriate intensity ofCl isotope peak (Figure 3.4.12 (A)), which 
readily lost a 32 mass unit corresponding to a methanol molecule, to give an ion at 
m/z 293 as shown in the MS/MS spectrum (Figure 3.4.12 (B)). Therefore, the 
molecular weight ofmetabolite-3 was determined to be 294 Da, and the ion at m/z 325 
corresponded to the methanol adduct of metabolite-3. Compared with the molecular 
weight ofmetabolite-1, metabolite-3 had a 14 mass unit more, and this suggested that 
two hydroxyl and one carboxylic acid groups were introduced into the parent p-Cl 
AAP (Figure 3.4.13). 
H O 
0 ~ ? - n " 0 ^ c i 
/~^‘ C O O H ^~‘ 
H O 
Figure 3.4.13 Structure of metabolite-3, 2-[(4-chlorophenyl)]amino-2-[4-(2,6-
dihydroxypyridyl)]ethanoic acid. 
�� 
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Substitution of the two hydroxyl groups were assigned at 3 and 5 position in the 
pyridine ring, which was demonstrated by the most intensive peak at m/z 183 in the 
� MS/MS spectrum (Figures 3.4.12 (B) and 3.4.14). Therefore, the structure of 
metabolite-3 was identified as 2-[(4-chlorophenyl)]amino-2-[4-(2,6-
dihydroxypyridyl)] ethanoic acid. 
H O ^ -
0 ~ ? - ^ r 0 ~ c i - H + 




: C - C - N " < J ^ V - C l 
_ 〇 ， H ^ H V _ ^ 
m/z183 
Figure 3.3.14 Possible fragment pattern of metabolite-3 in negative ion APCI MSMS. 
The fragment ion ofm/z 183 indicates the hydroxyl group can only present in 
the pyridine ring since hydroxyl group in benzene ring is difficult to remove (Herbert 
et aL, 1967). On the other hand, ifhydroxyl group in the carbon next to the amine, a 
loss of 18 mass unit represent the water molecule should be observed in the MS/MS 
spectrum. However, no such fragment pattem can be found. Again, hydroxylamine is 
unstable in that its formation is thermodynamically not favorable. 
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Both phase I and phase II forms, including glucuronide and sulphate 
conjugates, of metabolite-3 were found in the urine of rats dosed with;7-Cl AAP. 0-
� glucuronidation and 0-sulphation can occur on both phenol and carboxylic acid 
functional groups, however, the site(s) for these conjugations could not be determined 
in the present study. 
For metabolite-4, the HPLC/MS/MS analysis for fraction 2 showed the ion 
with 100 % intensity at m/z 247 corresponding to the quasi-molecular ion in the 
negative ion APCI MS/MS spectrum (Figure 3.4.15 (B)), and the highest mass ion at 
m/z 307 (observed in the MS spectrum) resembling its acetic acid adduct, and its 
corresponding C1 isotope ion indicating drug-related metabolite (Figure 3.4.15 (A)). 
Therefore, the molecular weight of this metabolite was determined as 248 Da, which 
has one more oxygen atom than that ofthe parent p-Cl AAP (molecular weight of232 
Da). Furthermore, a direct probe positive electron impact (EI) MS analysis was 
carried out for elucidation of the structure of metabolite-4. In the EI-MS spectrum 
(Figure 3.4.16 (A)), molecular ion at m/z 248, and other two diagnostic fragment ions 
at m/z 232 and 217 were observed. The mass fragment pattem in Figure 3.4.16 
suggests that this metabolite is A -^oxide of p-Cl AAP. A similar mass spectrometric 
data obtained from a positive ion CI-MSMS analysis using a direct probe technique 
further confirmed the identity ofmetabolite-4 (Figure 3.4.16 (B)). The oxygen in the 
A -^oxide dissociates easily in MS/MS analysis, and a loss of oxygen atom from N-
oxide compounds is a common fragmentation (Herbert et al., 1967). Therefore, 
metabolite-4 was definitively identified as A -^oxide of>-Cl AAP, and its structure is 
shown in Figure 3.4.18. 
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Figure 3.4.15 Negative-ion mass spectra of metabolite-4 from respective chromatograms of 
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0 ~ � [ f " 0 ~ c i 
m/z217 
Figure 3.4.17 Possible fragment pattem of metabolite-4 in positive ion EI-MS. 
o " & t 3 n ^ > c 1 
Figure 3.4.18 Structure of metabolite-4, AA-[4-(chlorophenyl)]-l-[4-(pyridyl N-
oxide)]ethylamine. 
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Only phase II metabolites of 7V-oxide of 户-Cl AAP (metabolite-4), including 
glucuronide and sulphate conjugates, were found in the rat urine. The possible site for 
� conjugation is nitrogen atom in the arylamine moiety. A^-glucuronides and 7V-sulphates 
formed from arylamine have been reported for a wide range of drugs and xenobiotics 
(Gibson and Skett, 1994). It is interesting to note that, as discussed in next section, the 
relative amounts of glucuronide and sulphate of A^-oxide of p-C\ AAP found in rat 
urine were 1 : 2. This observation suggested that arylamine sulphation is more 
favourable than arylamine glucuronidation. This metabolic preference is also reported 
for other drugs, for example, only arylamine sulphate conjugate of paracetamol was 
found (Gibson and Skett, 1994). 
Fraction 3 only contained one compound, corresponding to metabolite-5, as 
demonstrated in the chromatograms of HPLC/MS/MS analysis (Figure 3.4.19). The 
negative ion APCI-MS spectrum (Figure 3.4.20 (A)) exhibited a highest mass ion at 
m/z 367, whilst the corresponding MS/MS spectrum (Figure 3.4.20 (B)) confirmed the 
quasi-molecular ion at m/z 247 and the ion at m/z 367 represented an acetic acid 
adduct of metabolite-5. Therefore, the molecular weight of metabolite-5 is 248 Da, 
which is 16 mass unit more than that of the parent p-C\ AAP. The positive ion 
HPLC/MS/MS analysis (not shown) provided similar results, and no further fragment 
ions were observed. Therefore, based on the HPLC/MS/MS results, metabolite-5 was 
tentatively assigned as 3-hydroxylated p-Cl AAP, namely 7V-[4-(chlorophenyl)]-l-[4-
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Figure 3.4.20 Negative-ion mass spectra of metabolite-5 from respective chromatograms of 
Figure 3.4.19. A) MS spectrum, B) MS/MS spectrum of metabolite-5. 
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H O 
� ^ c y h - ^ y ^ ' cH3 u 
Figure 3.4.21 Structure of metabolite-5, 7V-[4-(chlorophenyl)]-l-[4-(2-
hydroxypyridyl)] ethylamine. 
As mentioned in previous metabolites, the hydroxyl group in metabolite-5 is 
most possibly in either pyridine or benzene ring. However, as the substituted chloride 
deactivates benzene ring via electron withdrawing, the hydroxylation at pyridine ring 
is much thermodynamically favourable. 
For this metabolite, only phase II metabolites, including glucuronide and 
sulphate conjugates were identified in the urine of rats administered with p-C\ AAP, 
and their amounts were determined to be 1 : 1. For both conjugates, 0-
glucuronidation and 0-sulphation may predominate. 
HPLC/MS/MS analysis of fraction 4 demonstrated that this fraction only 
contained one compound, metabolite-6 (Figure 3.4.22). Since negative ion MS did not 
show any signal for this compound, a positive ion (HPLC/MS/MS analysis with APCI 
interface was conducted. In the positive ion APCI-MS spectrum (Figure 3.4.23 (A)), 
an ion at m/z 247 and 249 (C1 isotope peak) corresponding to the quasi-molecular ion 
was observed. The MS/MS spectrum of this quasi-molecular ion exhibited a 
characteristic ion at m/z 219, corresponding to a loss of CO molecule (Figure 3.4.23 
(B)). 
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Figure 3.4.23 Positive-ion mass spectra of metababolite-6 from respective chromatograms of 
Figure 3.4.22. A) MS spectrum, B) MS/MS spectrum of metabolite-6. 
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The loss of CO from aldehyde in MS is common and often observed in the MS 
spectra of other aldehyde compounds (Herbert et al., 1967). Therefore, metabolite-6 
� was identified as ；？-amino aldehyde of the parent drug, named as 2-[4-
(chlorophenyl)]amino-2-[4-(pyridyl)]ethanal. The structure of metabolite-6 is shown 
in Figure 3.4.24, and its mass fragmentation in Figure 3.4.25. 
N ^ H _ N H " ^ ^ C I 
^ ~‘ H C = 0 ^ ~ , 
Figure 3.4.24 Structure ofmetabolite-6, 2-[4-(chlorophenyl)]amino-2-[4-(pyridyl)]ethanal. 
Only the sulphate conjugate of metabolite-6 was found as the urinary metabolite oip-
C1 AAP. Similar to metabolite-4, conjugation can only occur at arylamine nitrogen, 
thus sulphation predominated. 
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N ^ " P H ^ > " C I + H+ 
^ ~丨 H C = 0 “ 
、 m/z247 [M + ir 
0 " S : H ^ ^ C I + H+ 
m/z219 
Figure 3.4.25 Possible fragment pattem ofmetabolite-6 in positive ion APCI-MS/MS. 
In the present study, five novel metabolites of p-C\ AAP, in the forms of 
glucuronides and sulphates, were found in the urine of rats dosed with p-C\ AAP. 
These metabolites were tentatively identified as A/-[4-(2-hydroxychlorophenyl)]-l-[4-
(2,6-dihydroxypyridyl)]ethylamine (metabolite-1), N-[4-(chlorophenyl)]-l -hydroxy-1 -
[4-(pyridyl)]ethylamine (metabolite-2), 2-[4-(chlorophenyl)]amino-2-[4-(2,6-
dihydroxypyridyl)]ethanoic acid (metabolite-3), 7V-[4-(chlorophenyl)]-l-[4-(pyridyl 
A^-oxide)]ethylamine (metabolite-4) and A^-[4-(chlorophenyl)]-l-[4-(2-
hydroxypyridyl)]ethylamine (metabolite-5). The phase I metabolites of 7V-[4-
(chlorophenyl)]-l -hydroxy- l-[4-(pyridyl)]ethylamine (metabolite-2) and 2-[4-
(chlorophenyl)]amino-2-[4-(2,6-dihydroxypyridyl)]ethanoic acid (metabolite-3) were 
also isolated from the rat urine. In addition, another novel metabolite, 2-[4-
(chlorophenyl)]amino-2-[4-(pyridyl)]ethanal (metabolite-6), was identified as its 
arylamine sulphate conjugate only. With regard to the structures of the identified 
Chapter Three 1^ 
metabolites, only p-C\ AAP A^-oxide was definitively characterized, while others were 
tentatively assigned. As this is only a preliminary metabolic study on j^-Cl AAP, 
� further studies including NMR and IR spectrometric analysis are required for 
definitive identification of the metabolites. 
As shown in Figure 3.4.26, the urinary metabolic pathway of ；？-Cl AAP was 
proposed. Although P_amino alochol, the proposed pharmacologically active 
metabolite of p-C\ AAP was not observed, two metabolites, namely 2-[4-
(chlorophenyl)] amino-2-[4-(pyridyl)]ethanal (metabolite-6) and 2-[4-
(chlorophenyl)]amino-2-[4-(2,6-dihydroxypyridyl)]ethanoic acid (metabolite-3), were 
found. As indicated in Figure 3.4.26, during the formation of these two metabolites, a 
precursor, p_amino alcohol, should be generated in the body first. The present results 
indicated that the major metabolic pathways for p-Cl AAP include phenyl, a- and P_ 
carbon hydroxylation, iV-oxidation, glucuronidation and sulphation. For the 
conjugates, 0-glucuronidation and arylamine sulphation are the major pathways. 
As 2-[4-(chlorophenyl)]amino-2-[4-(pyridyl)]ethanal (metabolite-6) was 
identified as a metabolite of j^-Cl AAP, the possibility exists that it is further oxidized 
to form an a-amino acid inside the body. Then two metabolites together with the 
substituted a-amino acid metabolite, 2-[4-(chlorophenyl)]amino-2-[4-(2,6-
dihydroxypyridyl)]ethanoic acid (metabolite-3) identified, might act as the analogues 
of GABA or other excitatory amino acids to produce the antiepileptic effect of p-C\ 
AAP. Further studies on the pharmacological effects of these metabolites are 
necessary to verify this inference. 
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Figure 3.4.26 Possible urinary metabolic pathway of p-C\ AAP. 
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3.4.2 QUANTITATIVE STUDIES 
As the calibration curves for the p-Cl AAP in bio-fluids have been constructed 
� as mentioned in Chapter 2, the urinary excretion of p-Cl AAP in rats was determined 
and the data are presented in Table 3.4.2 and Figure 3.4.27. 
Table 3.4.2 Urinary excretion of j^ -Cl AAP in rats. 
Amount of>Cl AAP* (%)** 
Pretreatment 0 - 24 hour 24-48 hour 
Phenobarbitone 0.28 土 0.07 0.04 ± 0.002~~ 
Non-phenobarbitone 0.18±0.01 0.014±0.0008 
* Mean 土 s.d. (n = 5) 
** The amount ofthe p-Cl AAP in urine was expressed as percentage of the 
amount dosed in rats. 
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Figure 3.4.27 Urinary excretion of p-Cl AAP in rats, (n = 5) 
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For the phenobarbitone pretreated rats, after 24 and 48 hours, the percentage 
of>-Cl AAP found in urine sample was 0.28 土 0.07o/o and 0.04 士 0.002o/o with respect 
. to the amount of p-C\ AAP administered in the rats, respectively. For the non-
phenobarbitone pretreated rats, the corresponding values were 0.18 士 O.OP/o and 
0.014 士 0.0008o/o, respectively. Only trace amounts of the intact parent drug were 
found in the urine samples. This suggests that the novel anticonvulsant was either 
highly metabolized or retained inside the body. Trace amounts of p-C\ AAP in the 
urine and almost no metabolite was found in urinary samples after 48 hours. For the 
metabolic studies, only those samples collected in the 0 - 24 hour period were 
analyzed. 
It is interesting to note that the amount ofp-Cl AAP excreted was 55 % higher 
in phenobarbitone pretreated rats than in the non-phenobarbitone pretreated rats, for 
both the 0 - 24 hours (the difference here was not statistically significant, P > 0.05) 
and 24 - 48 hours samples (P < 0.0001). Phenobarbitone pretreatment on rats has been 
reported to stimulate the renal excretion of j^-aminohippuric acid (Storch, 1975, 1976 
and 1977) and ioglycamic acid (IGA) (Fleck, 1991). Hence, our results may also 
suggest that phenobarbitone pretreatment may enhance the renal excretion of the 
intact p-C\ AAP. Further experiments are necessary to determine whether the 
increased excretion of p-C\ AAP is due to the stimulation of the glomerulus or by 
other means. 
As there was a lack of authentic samples of the putative metabolites, it was 
impossible to determine the actual amount of the metabolites excreted from urine. 
However, the relative amounts of different urinary metabolites from different 
pretreated rats could be determined as described in section 2.5.6. The relative amounts 
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of metabolite-2 and metabolite-3 in phenobarbitone and non-phenobarbitone 
pretreated rats are tabulated in Tables 3.4.3 and 3.4.4, and shown graphically in 
, Figures 3.4.28 and 3.4.29, respectively. Unless otherwise stated, all reference values 
for comparison of the amount of each metabolite were set at 100 %. 
Table3.4.3 Metabolite-2 and metabolite-3 excreted from 0-24 hour urine of the 
phenobarbitone pretreated rats administered withp-C\ AAP (80 mg/kg, i.p.). 
(n = 5) 
Treatment on urine sample Metabolite-2 Metabolite-3 
Phase I 100±5.7% 100±0 .3%~~ 
p-glucuronidase deconjugation 209.3 士 9.9 % 147.6 ± 20.3 % 
p-glucuronidase / sulphatase deconjugation 270.3 士 29.8 % 259.7 士 30.0 % 
Table3.4.4 Metabolite-2 and metabolite-3 excreted from 0-24 hour urine of the non-
phenobarbitone pretreated rats administered withp-C\ AAP (80 mg/kg, i.p.). 
(n = 5) 
Treatment on urine sample Metabolite-2 Metabolite-3 
Phase I 100±5.8% 100±10.1 % 
P-glucuronidase deconjugation 146.8 士 9.6 % 141.5 土 6.7 % 
P-glucuronidase / sulphatase deconjugation 183.3 土 13.9 % 233.5 士 8.7 % 
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Figure 3.4.28 Metabolite-2 and metabolite-3 excreted from 0-24 hour urine of the 
phenobarbitone pretreated rats administered withp-C\ AAP (80 mg/kg, i.p.). 
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Figure 3.4.29 Metabolite-2 and metabolite-3 excreted from 0-24 hour urine of the non-
phenobarbitone pretreated rats administered withp-C\ AAP (80 mg/kg, i.p.). 
(n = 5) 
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All putative metabolites found without enzymatic deconjugation were phase I 
metabolites and normalised to 100 % (as mentioned in section 2.5.6). The amount of 
� metabolites measured after deconjugation was compared with those without 
deconjugation. For the phenobarbitone pretreated rats, after P-glucuronidase and p-
glucuronidase / arylsulphatase deconjugation, the relative amounts of metabolite-2 
were 209.3 土 9.9 % and 270.3 土 29.8 %, respectively. For the non-phenobarbitone 
pretreated rats, they were 146.8 士 9.6 % and 183.3 土 13.9 %, respectively. Hence, the 
relative amounts of phase I, glucuronide and sulphate conjugates of metabolite-2 for 
the phenobarbitone pretreated rats were 1 : 1 : 0.6, respectively. For the non-
phenobarbitone pretreated rats, they were 1 : 0.47 : 0.36, respectively. It showed that 
metabolite-2 formed phase I, and both glucuronide and sulphate conjugates during the 
metabolism ofp-C\ AAP. 
In the case of metabolite-3, in phenobarbitone pretreated rats, the relative 
amounts after p-glucuronidase deconjugation and p-glucuronidase / aryl sulphatase 
deconjugation were 147.6 士 20.3 % and 259.7 土 30.3 %, respectively. For the non-
phenobarbitone pretreated rats, they were 141.5 土 6.7 % and 233.5 士 8.7 %, 
respectively. Hence, the relative amounts of metabolite-3 in the forms of phase I, 
glucuronide and sulphate conjugates, for the phenobarbitone pretreated rats, were 1 : 
0.48 : 1.12, respectively. For the non-phenobarbitone pretreated rats, they were 1 : 
0.42 : 0.92, respectively. The relatively large amount of sulphate conjugate resulted 
when compared with those of glucuronide conjugate, showed that metabolite-3 
displayed a much greater tendency to undergo sulphate conjugation than glucuronide 
conjugation. 
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The comparison of urinary excretion of metabolite-2 and metabolite-3 
between the phenobarbitone and non-phenobarbitone pretreated rats is shown in 
� Tables 3.4.5 and 3.4.6, and Figures 3.4.30 and 3.4.31. 
Table3.4.5 Comparison of urinary excretion (0-24 hour) of metabolite-2 between 
phenobarbitone and non-phenobarbitone pretreated rats administered with p-C\ 
AAP (80 mg/kg, i.p.) (n = 5) 
Non-phenobarbitone Phenobarbitone 
pretreated rats pretreated rats 
Phase I metabolite 100i5.8% 62.6±4.1 % 
Glucuronide conjugate 100 土 17.5 % 166.0 士 5.0 % 
Sulphate conjugate 100 土 25.8 % 225.1 土 69.8 % 
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Figure 3.4.30 Comparison of urinary excretion (0-24 hour) of metabolite-2 between non-
phenobarbitone and phenobarbitone pretreated rats administered with p-C\ 
AAP (80 mg/kg, i.p.) (n = 5). 
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Table3.4.6 Comparison of urinary excretion (0-24 hour) of metabolite-3 between 
phenobarbitone and non-phenobarbitone pretreated rats administered with p-C\ 
AAP (80 mg/kg, i.p.) (n 二 5) 
� . 
Non-phenobarbitone Phenobarbitone 
pretreated rats pretreated rats 
Phase I metabolite 100士10.1 % 95.2±0.3% 
Glucuronide conjugate 100 士 11.7 % 126.9 土 53.7 % 
Sulphate conjugate 100 土 8.9 % 124.3 士 23.0 % 
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Figure 3.4.31 Comparison of urinary excretion (0-24 hour) of metabolite-3 between non-
phenobarbitone and phenobarbitone pretreated rats administered with p-C\ 
AAP (80 mg/kg, i.p.) (n = 5). 
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When the amounts of metabolite-2 and its conjugates excreted from the non-
phenobarbitone pretreated rats are set at 100 %, those excreted from phenobarbitone 
� pretreated rats can be directly compared. After phenobarbitone pretreatment, the 
amount ofthe phase I metabolite significantly decreased (P < 0.001) (from 100 士 5.8 
% to 62.6 土 4.1 %) while the amounts of glucuronide and sulphate conjugates of 
metabolite-2 excreted markedly increased (from 100 士 17.5 % and 100 士 25.8 % to 
166 士 5.0 % and 225.1 士 69.8 %, respectively). A statistically significant increase in 
excretion (P < 0.05) was observed in the case of glucuronide conjugate (by 66 %). 
The amount of sulphate conjugate also increased (by 125 %). However, no 
statistically significant difference (P > 0.05) was obtained for sulphate conjugate, 
which might be due to relatively higher inter subject variations with the small number 
of animals examined (n = 5). Metabolite-2 exists in both phase I and phase II forms 
and several enzymes involved in the formation of metabolite-2. Phenobarbitone is 
cytochrome P450 enzyme inducer (Gibson and Skett, 1994). Metabolism of>-Cl AAP 
to metabolite-2 in phase I form is mediated by cytochrome P450 enzyme system 
which, might be the rate determining step for metabolism of the parent drug. Once 
phase I metabolite-2 is formed, it might quickly undergo phase II metabolism. Hence, 
more glucuronide and sulphate conjugates of metabolite-2 were found in the urine of 
phenobarbitone pretreated rats. 
For the metabolite-3 of p-Cl AAP, similar comparison was made as with the 
studies on metabolite-2, i.e. treating the amount of metabolite-3 in non-
phenobarbitone pretreatment as 100 %. Regarding phase I metabolite, the relative 
amount of metabolite-3 in phenobarbitone pretreated rat was 95.2 土 0.3 %. This was 
approximately the same in amount as in non-phenobarbitone pretreated rats. 
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For the glucuronide and sulphate conjugates, the relative amount for phenobarbitone 
pretreated rats was 126.9 土 53.7 % and 124.3 土 23.0 % respectively. Only slight 
� increases in the amounts of both conjugates with about 27 and 24 % were observed. 
This suggest phenobarbitone has no or very weak effect on the metabolism of>-Cl 
AAP to metabolite-3. 
It was found that only after the deconjugation of the rat urine samples could 
metabolite-1, -4 and -5 be detected, indicating that these three metabolites were 
present as phase II conjugates only. The relative amounts of these three metabolites in 
phenobarbitone and non-phenobarbitone pretreatment are shown in Tables 3.4.7 and 
3.4.8，and Figures 3.4.32 and 3.4.33. 
Table3A7 Phase II metabolites-1, -4 & -5 excreted from 0-24 hour urine of 
phenobarbitone pretreated rats administered withp-C\ AAP (80 mg/kg, i.p.). 
(n = 5) 
__—_^_——^^——<—^^^^^^^^^^^^^^^^^^^^^^—^——^^—^——^—» 
Type ofdeconjugation Metabolite-1 Metabolite-4 Metabolite-5 
P-glucuronidase 100±11.3% 100±7.3% 100+10.2% 
p-glucuronidase/aryl sulphatase 148.9 土 11.3 % 354.9 土 67.3 % 202.4 士 15.2 % 
Table 3.4.8 Phase II metabolites-1, -4 & -5 excreted from 0-24 hour urine of non-
phenobarbitone pretreated rats administered withp-C\ AAP (80 mg/kg, i.p.). 
(n = 5) 
Type ofdeconjugation Metabolite-1 Metabolite-4 Metabolite-5 
p-glucuronidase 100±15.1 % 100±30.7% 100127%~~" 
p-glucuronidase/aryl sulphatase 144.4 士 18.0 % 298.7 士 27.5 % 394.7 土 144.7 % 
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Figure 3.4.32 Phase II metabolite-1, -4 & -5 excreted from 0-24 hour urine of 
phenobarbitone pretreated rats administered with p-Cl AAP (80 mg/kg, i.p.). 
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For comparison, the amounts of metabolite-1, -4 and -5 determined after 
glucuronidase deconjugation were set at 100 % as described in section 2.4.6. In 
� phenobarbitone pretreated rats, the relative amounts of sulphate conjugate of 
metabolites-1, -4 and -5 measured after the aryl-sulphatase deconjugation, were found 
to be 48.9 士 19.8 %, 254.9 土 67.3 % and 102.4 士 15.2 %, respectively. For the non-
phenobarbitone pretreated rats, they were 44.4 土 18.0 %, 198.7 士 27.5 % and 294.7 士 
144.7 o/o, respectively. Both metabolites-4 and -5, after P-glucuronidase/aryl 
sulphatase deconjugation, showed a significant increase compared with those 
subjected only to P-glucuronidase deconjugation (P < 0.05) in the phenobarbitone 
pretreated rats (Table 3.4.7), whereas in non-phenobarbitone pretreated rats, only 
metabolite-4 gave a significant increase (P < 0.01). Even though other metabolites in 
the different pretreatment groups did not show any statistically significant difference, 
a marked increase in the amount of metabolites was still observed after P_ 
glucuronidase / aryl sulphatase deconjugation. The ratio of glucuronide to sulphate 
conjugate ofmetabolites-1, -4, and -5 were 1 : 0.49, 1 : 2.5 and 1 : 1，respectively for 
the phenobarbitone pretreated rats, and 1 : 0.44, 1 : 2 and 1 : 2.9, respectively for the 
non-phenobarbitone pretreated rats. 
In the phenobarbitone pretreated rats, it was found that the amount of 
glucuronide conjugate of metabolite-1 differed from the sulphate conjugate by two-
fold, suggesting metabolite-1 had a tendency to form the glucuronide conjugate. 
However, for metabolite-4, nearly 72 % was converted to the sulphate conjugate. For 
metabolite-5, the ratio of both glucuronide and sulphate conjugates was 1 : 1, 
indicating an equal preference for the formation of each conjugate. 
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In the non-phenobarbitone pretreated rats, the sulphate conjugate formed was 
31 % for metabolite-1 and nearly 66 % for metabolite-4. These results were 
� comparable to those obtained for phenobarbitone-pretreated rats, in that more 
glucuronide was present for metabolite-1, while sulphate conjugate was predominant 
for metabolite-4. Whereas, for metabolite-5, the glucuronide constituted nearly 75 % 
of the total amount of the metabolites, which was different from that obtained for 
phenobarbitone pretreated rats. 
The comparison of urinary excretion of phase II metabolite-1, -4 and -5 
between phenobarbitone and non-phenobarbitone pretreated rats is shown in Table 
3A9and Figure3.4.34. 
Table 3.4.9 Comparison ofurinary excretion (0-24 hour) ofphase II metabolite-1, -4 and -5 
between phenobarbitone and non-phenobarbitone pretreated rats administered 
withp-C\ AAP (80 mg/kg, i.p.). (n 二 5) 
Metabolite Non-phenobarbitone Phenobarbitone 
pretreated rats pretreated rats 
Glucuronide Conjugate 1 100±15.1% 87.2 土 9.9 %~~ 
4 100±30.7o/o 123.7±9.0o/o 
5 100±27.0o/o 257.5 ±26.3o/o 
Sulphate Conjugate 1 100 土 40.2 % 210.2 土 108.0 % 
4 100±17.0o/o 141.8±28.3o/o 
5 100±41.0o/o 116.2±9.5o/o 
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Figure 3.4.34 Comparison ofurinary excretion (0-24 hour) of phase II metabolite-1, -4 and 
-5 between phenobarbitone and non-phenobarbitone pretreated rats 
administered with p-Cl AAP (80 mg/kg, i.p.) (n = 5). 
In considering the amounts of the metabolites found in non-phenobarbitone 
pretreated rats as 100 %, the relative amounts of metabolite-1 as glucuronide and 
sulphate conjugates in phenobarbitone pretreated rats could be determined, and these 
were found to be 87.2 土 9.9 % and 210.2 士 108.8 % (Table 3.4.9), respectively. This 
showed that phenobarbitone pretreatment did not affect glucuronide formation 
(statistically insignificant) of metabolite-1, however it significantly increased its 
sulphation to about 110 %. 
For metabolite-4, the relative amounts of glucuronide and sulphate conjugates 
in phenobarbitone pretreated rats determined were 123.7 土 9.0 % and 141.8 士 28.3 % 
compared with those found for non-phenobarbitone pretreated rats. 
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Although no statistical significance was obtained, a marked increase in the amount of 
both conjugates of metabolite-4 in phenobarbitone pretreated rats was observed. The 
� increase in the amount ofthese two conjugates was about 24 and 42 %, respectively. 
For metabolite-5, the amounts of glucuronide and sulphate conjugates in the 
phenobarbitone pretreated group relative to those in the control group were 257.5 士 
26.3 % and 116.2 士 9.5 %, respectively. A statistically significant increase by 158 % 
(P < 0.01) in the amount of glucuronide conjugate was found. However, there was 
only a slight (statistically insignificant) increase (by 16 %) in sulphate conjugate. 
Phenobarbitone is an inducer for the phase I metabolizing enzyme system, 
cytochrome P450 monooxygenases (Waxman and Azaroff, 1992). It is also an inducer 
of many glucuronosyl transferases (Bock et al., 1973; Lilienblum et al., 1982; 
Watkins and Klaassen, 1982; Watanable and Matsui, 1984), involved in the 
metabolism of morphine, chloramphenicol and bilirubin. The results suggest 
phenobarbitone might enhance the activity of the enzymes, including UDP-
glucuronosyl transferases, which are involved in the phase II metabolism of p-Cl 
AAP, especially for the glucuronidation of metabolites-2, -4 and -5. 
As phenobarbitone also enhances the expression of hydroxysteroid 
sulphotransferase a (STa) (Werle et al., 1993), it will therefore enhance the activity of 
sulphotransferase. It might also enhance the activity of the sulphotransferase involved 
in the sulphation ofthe metabolites-1, -2 and -4 but not for metabolite-3 and -5 ofp-
C1 AAP. Furthermore, sulphation of the metabolites may also be mediated by other 
sulphorylase enzymes, such as ATP-sulfurylase and APS-kinase, which might also be 
induced by phenobarbitone (although there is no previous report). As a result, a 
prominent increase in the excretion of glucuronide and/or sulphate conjugates of 
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metabolites-1, -2, -4 and -5 was observed after three days pretreatment of 
phenobarbitone. 
� In addition, phenobarbitone induces cytochrome P450 enzymes, thereby 
increasing the phase I metabolism of p-C\ AAP to yield more metabolites either in 
their phase I form or further biotransformed to their phase II forms. Hence, the total 
amount of the metabolite-1, -2, -4 and -5 present in rat urine increased in 
phenobarbitone pretreated rats. 
It is interesting to note that metabolite-6 was only found after the P_ 
glucuronidase / aryl sulphatase deconjugation ofthe rat urine samples but not after the 
P-glucuronidase deconjugation. This suggested that metabolite-6 formed only the 
sulphate conjugate. Furthermore, metabolite-6 was not found in non-deconjugation 
samples. This confirms metabolite-6 undergoes phase II metabolism but without 
appearing as any form of phase I metabolite in urine. A comparison of its relative 
amount in both phenobarbitone and non-phenobarbitone pretreatment is shown in 
Table 3.4.10 and Figure 3.4.35. 
Table3.4.10 Comparison of urinary excretion (0-24 hour) of phase II metabolite-6 
between phenobarbitone and non-phenobarbitone pretreated rats with p-C\ 
AAP (80 mg/kg, i.p.). (n 二 5) 
Non-phenobarbitone Phenobarbitone 
pretreated rats pretreated rats 
Sulphate Conjugate 100±23.1 % 107.0±36.9% 
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Figure 3.4.35 Comparison ofurinary excretion (0-24 hour) ofphase II metabolite-6 between 
phenobarbitone and non-phenobarbitone pretreated rats with p-Cl AAP 
(80 mg/kg, i.p.). (n 二 5) 
The relative amount of metabolite-6 in urine obtained from non-
phenobarbitone pretreated rats was treated as 100 %, and the relative amount in 
phenobarbitone pretreated rats was 107.0 土 36.9 %. No significant difference between 
two groups was found which suggests phenobarbitone had no effect on metabolite-6 
of>-Cl AAP, as the enzymes involved were not induced by phenobarbitone. 
Six metabolites of>-Cl AAP were excreted in rat urine, of which metabolites-
2 and -3 were found to undergo both phase I and phase II metabolism. The remaining 
metabolites appeared to undergo phase II metabolism only. Both glucuronide and 
sulphate conjugates were formed for all except metabolite-6, which yielded the 
sulphate conjugate only. In the phenobarbitone pretreated rats, metabolites-1, -2, -4 
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and -5 showed a prominent increase in urinary excretion. From these metabolites, 
only metabolite-2 showed an increase in the amount of glucuronide and sulphate 
� conjugates; the other metabolites exhibited an increased in the amount of either 
glucuronide conjugate or sulphate conjugate. 
In the quantitation of some of the metabolites, a high standard deviation was 
observed. This might be due to a fluctuation in the physiological state ofdifferent rats, 
hence affecting the enzyme activities of those enzymes involved in metabolism ofp-
C1 AAP. As a result, the relative amount of the metabolites determined might vary. 
Furthermore, due to the unavailability of authentic standards, the assays used for the 
quantitation of the metabolites of p-C\ AAP could not be fully validated. However, 
this study has provided a preliminary quantitative assay for the metabolites and the 
determination oftheir relative amounts excreted from urine. This may also contribute 
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In conclusion, the physicochemical properties of five structurally related 
aminoalkylpyridines 0^-F, p-Cl, p-Br, j9-CH3, and m-CF3 AAPs) have been 
� investigated. These include partition coefficient (K°w), aqueous solubility at various 
temperatures, enthalpy of solution (AH'), the melting point (Tm) and enthalpy and 
entropy of fusion (AH^ and AS )^. The K\ of the p-F, p-Cl, p-Br, and p-CR3 AAPs 
were statistically indistinguishable within experimental errors while the K% 0fm-CF3 
AAP was significantly lower than the other AAPs, which may be related to the 
increased ionization ofthe m-CF3 substituted aniline leading to increased partition of 
the compound into the aqueous phase. The solubilities of AAPs in water increased 
with an increase in temperature and depended on the substituent on the benzene ring 
ofAAPs (in the order: p-F > p-CH3�p-Cl > p-Br > m-CF3). The thermogravimetric 
analysis and DSC revealed that AAPs do not contain any solvent of crystallization 
and are relatively thermostable. 
A simple, sensitive and specific HPLC assay has been developed and validated 
for p-Cl AAP in rat blood and urine. The assay was reproducible with overall intra-
and inter-day variations of less than 13 % and 18 %. The accuracy of the developed 
assay was acceptable with a range of about 83 to 98 % for blood and 86 to 99 % for 
urine samples. The extraction recovery of p-Cl AAP and limit of detection were 92 土 
3.0 % and 100 ng/ml, respectively (Lin. et aL 1998). This assay was used in the 
subsequent quantitation of p-C\ AAP in rat biofluids. 
Preliminary pharmacokinetic studies were performed in the conscious rats 
after intravenous administration of p-Cl AAP. The half-life was 5.0 hours and the 
clearance was 1779.4 ml/hr. The volume of distribution was 12.71 L. The area under 
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curve (AUC) was 11.84 ^ig/ml-hr. The extensive extracellular distribution may be due 
to the high lipophilic property of this novel anticonvulsant. 
� Urinary metabolic studies were conducted in rats by administration of;7-Cl 
AAP intraperitoneally and six novel metabolites were found. On-line HPLC analysis 
ofthe found metabolites enabled their tentative identification, and they were named as 
Ar.[4-(2-hydroxychlorophenyl)]-l-[4-(2,6-dihydroxypyridyl)]ethylamine (metabolite-
1)，Ar-[4-(chlorophenyl)]-l-hydroxy-l-[4-(pyridyl)]ethylamine (metabolite-2), 2-[4-
(chlorophenyl)]amino-2-[4-(2,6-dihydroxypyridyl)]ethanoic acid (metabolite-3), N-
[4-(chlorophenyl)]-l-[4-(pyridyl A^-oxide)]ethylamine (metabolite-4), 7V-[4_ 
(chlorophenyl)]-l-[4-(2-hydroxypyridyl)]ethylamine (metabolite-5) and 2-[4-
(chlorophenyl)]amino-2-[(4-pyridyl)]ethanal (metabolite-6), respectively. All ofthem 
were shown to form glucuronide and sulphate conjugates except metabolite-6 which 
only formed sulphate conjugate. Metabolite-2 and -3 were excreted as both phase I 
and phase II forms, while the rests were as phase II metabolites. The metabolic 
pathway of the p-Cl AAP was proposed. Although p-amino alcohol was not directly 
found, amino aldehyde (metabolite-6) and amino acid (metabolite-3), the two 
metabolites using p-amino alcohol as a precursor during their formation, were 
identified. These metabolites might account for the anti-epileptic effect of the p-C\ 
AAP. 
The urinary excretion of the intact p-C\ AAP collected in 0 - 24 hours was 
found to be 0.28 士 0.07o/o and 0.18 士 0.002o/o of the dosed amount in the 
phenobarbitone and non-phenobarbitone pretreated rats. Trace amounts of the parent 
drug found in urine may be due to extensive metabolism and / or retention of>-Cl 
AAP inside the body. 
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Since authentic standards for the metabolites were not available, only relative 
amounts of the metabolites could be determined. Comparison between the 
� phenobarbitone and non-phenobarbitone pretreated rats showed that the overall 
amounts ofmetabolites were all increased by phenobarbitone pretreatment except for 
metabolite-3 and -6. Furthermore, a significant increase in the amount of glucuronide 
was only seen for metabolites-2, -4 and -5, while a marked increase in sulphate 
conjugation was only observed for metabolite-1, -2 and -4. This suggests that different 
enzymes are involved in the whole metabolic profile of p-C\ AAP, and 
phenobarbitone induces some of these enzymes. 
The studies described in this thesis have helped to shed some light on the 
metabolic pathway of aminoalkylpyridines, which is crucial for understanding the 
mechanism of action and potential toxicity of this new class of anticonvulsant. This 
information may also aid in the rational design of more effective and safer 
anticonvulsants for the treatment of epilepsy, and provide a rational basis for using 
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